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SUMMARY 
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Observatory 7925, Cape, South Africa. 
SUMMARY 
In patients with aplastic anaemia that respond to immunosuppressive therapy, quantitative, 
morphological and functional haematologic derangement have been reported. To explain 
these findings, abnormalities in the marrow stroma or the stem cell have been postulated. 
To define the relative contribution of each of the latter, the integrity of the bone marrow 
from sixteen patients that responded to anti-lymphocyte globulin and high dose methyl 
prednisolone was compared to normal individuals . 
Bone marrow mononuclear cells were divided into two fractions . From the first, stroma 
was cultured in aMEM containing 12.5% of both horse and foetal calf serum and 10-5 M 
hydrocortisone at 37° C in 5% CO2 in 90% humidity. The medium was changed weekly. 
Upon confluence, these stromal layers were studied morphologically and with cytospin 
preparations stained with Sudan black, 0 red oil, alkaline and acid phosphatases. The 
remainder was monocyte and lymphocyte depleted, CD 34+ progenitors were selected with 
paramagnetic beads and the population morphologically and immunophenotypically 
defined. To determine the functional status, control or patient CD 34+ progenitors, were 
suspended for two hours on normal or aplastic stroma for adherence to take place. The 
non-adhesive fraction was decanted by standardised washing and cultured for fourteen 
days in the presence of PHA-conditioned medium in the CFU-gm assay. Strama-adherent 
progenitors were covered with 0.3% agar and cultured for five days. Aggregates with more 
than twenty cells were scored (CFU-bl) . The remaining CD 34+ cells were cultured in the 
mixed colony assay with combinations of recombinant cytokines belonging to the G protein 
super-family and the tyrosine kinase group in dose response studies. 
Light density cells from patients with treated aplasia contained significantly fewer CD 34+ 
cells than those present in the control suspensions (mean 0.65%, SD 0.35% vs 1.62%, SD 
1.4%; p= 0.002) . Normal and aplastic stroma became confluent at three and four weeks . 
There was no difference on the morphology or the cytochemical stains between the two 
groups . Functionally, aplastic bone marrow stroma supported CFU-bl formation no 
differently from normal layers. However, CD 34+ precursors from the patients cultured on 
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control stroma resulted in significantly fewer CFU-bl (p= 0.0002,) and CFU-gm (p= 
0.0009). lbis work provides original evidence supporting the reduced clonogenicity of the 
corresponding populations of CFU-bl from patients with aplasia is unrelated to attachment 
to the stroma, but intrinsic to the CD 34+ cells. Moreover, this study shows for the first 
time that exposure of these progenitors to growth factors belonging to the G protein and 
tyrosine kinase receptor families have defective responses, correctable only at supra 
physiological concentrations, while effects on combinations containing c-kit ligand, appear 
preserved. 
Following immunosuppressive therapy, the bone marrow is repopulated by a 
hypoproliferative progenitor cell population which responds suboptimally to physiological 
cytokine stimulation. lbis suggests that abnormal interactions between receptors and their 
ligands or alterations in the signal transduction for cell division by the cytokines belonging 
to the G superfamily lead to suboptimal growth. 
25 August, 1993. 
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Introduction: In patients with aplastic anaemia lacking a bone marrow transplant 
option, immunosuppressive therapy can restore haematopoiesis. However, 
recovery is often incomplete and a proportion of the responders relapse. Extended 
follow up has indicated that in some, morphological and functional abnormalities 
of the blood elements occur, while in the bone marrow a marked reduction in the 
in vitro clonogenic pool has been described. In this group, particularly, clonal and 
malignant disorders may arise. 
Based on in vitro bone marrow culture and animal models, alterations in the 
myeloid microenvironment and quantitative or qualitative abnormalities of the 
haematopoietic stem cell have been proposed. The objective of the current thesis 
was to define the contributions of each pathophysiological defect in a well-defined 
cohort of patients. 
Patients: Thirty-six subjects that presented with features of severe aplasia received 
intravenously an infusion of horse anti-human lymphocyte globulin (ALG) 50 
mg/kg, following a bolus of 500 mg/kg methylprednisolone. Seventy one percent 
responded and at a median follow-up of four years, 65% are alive in response. Of 
this group, 16 were available and consented to participate in this study. 
Methods: This analysis consisted of morphological and quantitative 
determinations of the blood elements At the same time, peripheral blood functional 
tests were undertaken and these included generation of hydrogen peroxide, 
migration, phagocytosis and granulocytes killing of Candida Albicans, mitogenic 
lymphocyte responses and immunoglobulin production, bleeding time with platelet 
aggregometry and complement sensitivity of the red cell (Ham's test) by standard 
techniques. At the same time, bone marrow trephine biopsy and aspirates were 
obtained for morphological appraisal, cytogenetics studies with in vitro cultures of 
selected clonogenic progenitors and their marrow stroma and compared with 7 
normal volunteers. 
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For the evaluation of the haematopoiesis, bone marrow mononuclear cells were 
recovered by density gradient sedimentation and divided into two fractions . From 
the first, confluent stromal layers were prepared, while from with the second a 
lymphocyte and monocyte depleted population was obtained and enhanced for CD 
34+ cells by immunomagnetic selection. 
In cross-culture experiments, 1 xl04 CD 34+ progenitors from patients or controls 
were seeded on to preformed, confluent normal and aplastic bone marrow stromal 
layers. Adhesive precursors were scored for the formation of blastic colonies 
(CFU-bl) after 5 days incubation. Non adherent positively selected cells were 
defined in the CFU-gm assay. In a second step a corresponding aliquot of the CD 
34+ fraction was subjected to dose response studies in the mixed colony assay 
using combinations of erythropoietin, G, GM-CSF, IL-3 and c-kit ligand. 
Results: At a median of 4 years (range 1-8) following therapy, the median 
haemoglobin was 134.5 g/L (SD 27.2), MCV 98 fL (SD 7.17), granulocytes 2.9 
xl09fL (SD 1.89), lymphocytes of 1.65 xl09fL (SD 0.71), monocytes of 0.27 
x109fL (SD 0.2) and platelets 127 xl09fL (SD 80.44). Two patients developed a 
positive Ham's test with clinical features of paroxysmal nocturnal haemoglobinuria 
(PNH). Peripheral blood and bone marrow morphology was normal in three 
patients only. Variable degrees of dyserythropoiesis and megaloblastosis were seen 
in the rest. Although excessive numbers of blasts were not found, features of 
dysplasia were documented in one (2 patients), two ( 6 patients) and three cell 
lineages (5 patients) with abnormal localization of premature precursors (3 
patients). 
Suitable metaphases in 15 patients showed a constitutionally abnormal karyotype 
in one subject (47,:XX +C), while in 5, random chromosomal breaks and gaps 
ranging from 13 to 40% of cells were demonstrated. 
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Of 13 subjects tested, granulocyte functions were within the normal range in only 
one patient. For the group, these were significantly abnormal for the generation of 
peroxide at 2.79 11mol/min/l06 (SD 0.6) (p= 0.007) and phagocytosis at 53% (SD 
12.8) (p= 0.002). 
Results of mixed lymphocyte cultures and following stimulation of immunocytes 
with mitogens were normal in 12 patients but were subnormal in both subjects 
receiving cyclosporine therapy. Serum immunoglobulins were found to be within 
the normal range in all . Assessment of the platelet function demonstrated that the 
median bleeding time was 8.5 minutes (SD 3.4), was normal in five subjects of the 
fifteen tested, while in 3 it was more than 15 minutes. Aggregation studies were 
deranged in all the patients, with significantly sub optimal values for ADP, 
adrenaline, collagen and Ristocetin. 
Studies on the bone marrow showed that when mononuclear bone marrow cells 
were corrected to equal numbers, there were significantly fewer light density cells 
displaying CD 34 antigen in the aplastic group (mean 0.65%, SD 0.35%) 
compared to normal control (1.62%, SD 1.4%; p= 0.002). 
Both normal and aplastic stroma became confluent at a median of four weeks. 
They were morphologically and cytochemically indistinguishable, supporting 
equally the growth of CFU-bl from normal marrow selected cells (mean 117, SD 
20.4 vs 103 .1 SD 30.4 respectively); However, for the CD 34+ aplastic 
progenitors cultured on control layers this value was significantly reduced (mean 
41.06; SD 42.9; p= 0.0002, exact two tailed test) . In a similar manner, the stroma 
non-adherent positively selected population had a reduction in the number of CFU-
gm (mean 142.6; SD 104.8) when compared to normal precursors (mean 361.7; 
SD 91.3) CFU-gm with significantly lower total (CFU-bl+CFU-gm) clonogenic 
output (p= 0.0009). 
In the mixed colony assay, results were conflicting. At low concentrations of 
Erythropoietin, IL-3 and GM-CSF the positively selected aplastic progenitor cells 
had uniformly inferior colony formation compared to control cultures (p <0.05). 
However, they improved significantly, matching normal clonogenic growth with 
escalating doses. In contrast, cultures supplemented with growth factors 
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containing c-kit ligand, were significantly stimulated over the baseline values, 
proportionally more intensely than control progenitors. At effective concentrations, 
colony scores for BFU-e and CFU-gm were highest than any other combination, 
with values not significantly different from the control studies. Multivariate 
analysis segregated combinations containing appropriate concentrations of this 
ligand, suggesting that interactions originated by this cytokine were independent 
from all other combinations. 
From these simultaneous studies, it is concluded that even after an extended period 
following effective imrnunosuppressive therapy there are widespread 
morphological, functional and cytogenetic abnormalities in the haematopoitic cells. 
In vitro studies of the marrow progenitors demonstrated that the stroma derived 
from patients with aplasia is not morphologically different from control adherent 
layers, and supports the growth of control blastic colonies normally. Therefore, the 
reduction in the clonogenic growth of the corresponding populations of CFU-bl in 
the study group was unrelated to defective attachment to the marrow stroma, but 
intrinsic to the CD 34+ cells. 
Furthermore, exposure of these selected progenitors to growth factors belonging 
to the GTPase and tyrosine kinase receptor families, demonstrated defective 
responses to the former group that were correctable only at supraphysiological 
concentrations of cytokines. However, growth in culture supplemented with 
combinations containing c-kit ligand, which belongs to the later group, appeared 
preserved. 
It is reasoned that following imrnunosuppressive therapy the bone marrow is 
repopulated by a hypoproliferative progenitor cell population which responds 
suboptimally to physiological cytokine stimulation. This is consistent with the 
clinical experience. Although it remains unexplained, it suggests that in these bone 
marrow precursors either abnormal interactions between receptors and their 
ligands or alterations in the signal transduction for cell division by the cytokines 
belonging to the G superfamily lead to suboptimal growth. This explains the 
persistent subnormal blood values in patients with aplastic anaemia and may relate 
to the morphological and functional derangements described. 
CHAPTER 1 
APLASTIC ANAEMIA. BONE MARROW FAILURE OF 
MULTIPLE AETIOLOGIES 
1. 1 INTRODUCTION 
Normal haematopoiesis requires .the daily production of 1-2 x 1011 erythrocytes, 
granulocytes and platelets (Gale et al, 1981). These high generation rates and the 
relatively short life span of the differentiated cells mean that any compromise in the 
normal bone marrow function will produce serious clinical consequences. 
Aplastic anaemia is a disorder characterized by a partial or total arrest in the 
haematopoiesis due to a loss of this marrow regenerative capacity, leading to 
symptomatic pancytopenia that without appropriate therapy, will result in death 
from irreversible bone marrow failure . 
1. 2 IDSTORICAL BACKGROUND 
1. 2. 1 Historical Notes 
Paul Erlich in 1888 gave the first description of this disease, reporting peripheral 
blood pancytopenia with "yellow" hypo cellular marrow in a 21 year-old pregnant 
female (Erlich, 1888). He vividly described the triad of presenting symptoms: 
anaemia, infection and haemorrhage. Ehrlich deduced that the primary lesion was 
located in the haematopoietic tissues, expressing itself as failure of regeneration. 
However it was Chauffard who first gave the term aplasia to this syndrome 
(Chauffard, 1904). Since then several thousand patients have been described with 
similar clinical presentations. 
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Regrettably, in the early days marrow examination was not a routine diagnostic 
procedure, so that the terminology was employed interchangeably with other terms 
for bone marrow failure used at the time, including hypoplasia of the marrow, 
aleukaemia haemorrhagica, toxic paralytic anaemia, Fanconi's anaemia, Diamond-
Blackfan anaemia, etc. 
With the development of radiation biology during the 1940s, the bone marrow was 
recognized as a particularly susceptible organ to this type of radiation-induced 
damage, directed particularly at the stem cell pool. This observation led to the 
development of reproducible models for aplasia. Animal systems were designed to 
quantify marrow injury and study the kinetics of cell recovery. These methods 
suggested that in humans, bone marrow stem cell infusions might have a potential 
curative role in aplasia. 
However, reports of similar presentations, where pancytopenia was associated with 
th~ exposure to certain chemicals such as benzene derivatives, insecticides, drugs, 
and viral infections led to a more systematic search for the pathogenetic 
mechanisms initiating this syndrome. Recently, the epidemiology and the clinical 
course of the disease were more precisely defined, this led to practices where the 
supportive use of haematopoietic growth factors were combined with definitive 
therapies such as bone marrow transplantation or immune modulation, resulting in 
significant improvement in the outcome. 
1. 3 CLINICAL VARIANTS IN APLASTIC ANAEMIA 
1. 3. 1 Congenital Aplastic Anaemia 
The etiology of aplastic anaemia is unknown. Certain associations have been 
proposed, however. The occurrence of congenital somatic abnormalities in siblings 
with this disorder was first described by Fanconi (Fanconi, 1927). Following this 
report, children without the visceral and bony deformities or a clear-cut family 
history have also been cited (O'Gorman et al, 1974), bringing some confusion into 
the characterization of this group. 
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It was further proposed that the term of "constitutional anaemia" be used to 
describe this heterogeneous group of inherited diseases. This group included 
congenital hypoplastic anemia (Diamond-Blackfan) (Viskochil et al, 1990), familial 
aplastic anaemia with or without physical abnormalities and congenital 
amegakaryocytic thrombocytopenia. It was then suggested that the term Fanconi's 
anemia be applied to the familial marrow hypoplasia with somatic malformations, 
generally manifested during the first decade of life (Williams et al, 1985). 
However, the current working definition of Fanconi's Anaemia requires the 
demonstration in lymphocyte cultures of chromosomal breakage, with cross linking 
agents such as mitomycin C or diepoxibutane. Employing these criteria, a recent 
survey by the International Fanconi Anaemia Registry (IFAR) noted that 37% had 
no physical abnormalities, 31 % had no aplasia while 7% had neither (Auerbach et 
al, 1989, b). 
Inheritance in this type of genetic anaemia, follows an autosomal recessive pattern. 
Nevertheless, familial occurrence has also been described, with common HLA-
DR2 in another two reported cases. Since this phenotype is frequently found in 
patients with various autoimmune disorders, this could suggest a genetically 
inherited susceptibility in the development of the disease (Shimoda et al, 1990). 
Although the precise pathogenetic mechanisms still remain unknown, reduction in 
the clearance of oxygen radicals (Porfirio et al. 1989) and increased cellular 
sensitivity to DNA cross linking agents that appeared related to defective 
endonuclease activities, have been reported (Lambert et al, 1992). Furthermore, 
employing functional complementation methods, a specific mutant genetic product 
has been cloned representing a particular response to the DNA damage (Strathdee 
et al, 1992). 
On the cellular level, it is postulated that these abnormalities interact with the 
multiple signals that regulate the development of the haematopoietic and other 
cells. This is consistent with the recent finding of abnormal in vitro production of 
interleukin 6 (IL-6) by bone marrow cells. Since this cytokine is intimately involved 
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in the differentiation of early haematopoietic progenitors, these results may explain 
some of the described clinical and laboratory observations (Roselli et al, 1992). 
Clinical presentation occurs at a median age of 8 years (0-48) and is typically 
characterized by manifestations of progressive pancytopenia with marrow 
hypocellularity. Chromosomal analysis demonstrate cytogenetic abnormalities in 
high frequency (Athale et al, 1991). About 10% will develop acute leukaemia. 
Although the only cure for Fanconi's anerrua is bone marrow transplantation, 
initially patients are responsive to a variety of treatments. These typically include 
corticosteroids and androgenic steroids, individually or in various combinations 
(Rogers et al, 1989). The projected median survival is 27 years for those reported 
to IFAR (Auerbach et al, 1989 b). Male fertility is apparently reduced, with 
abnormal spermatogenesis and hypogonadism. Interestingly, as many female 
patients are now surviving beyond puberty despite an increased risk for toxemia, 
more successful pregnancies are being reported. During this period significant 
reductions in the blood counts are often observed. These may require supportive 
measures, which include blood product transfusions (Alter et al, 1992). 
The congenital anaemia described by Diamond and Blackfan is characterised by 
intense reticulocytopenia with a normocellular bone marrow, occurring during 
early childhood. Inheritance is heterogeneous, with examples of autosomal 
recessive, autosomal dominant, or more often of sporadic occurrences. Typically 
fetal haemoglobin is elevated with the fetal y I a pattern and over-expression of the 
i antigen on red cell membranes (Halperin & Freedman, 1989). 
Although in this disease the emphasis remams on the erythroid precursors, 
abnormalities in the lymphoid differentiation have also been described. In vitro 
studies indicate a diversity of defects, with resistance to erythropoietin (Tsai et al, 
1989) or IL-3 , and suggest an intrinsic progenitor cell disorder. Typically, patients 
respond rapidly to corticosteroid therapy, nevertheless relapses have been 
reported. Those failing to improve or needing large maintenance doses of 
hormonal treatment may require long term blood transfusions. In these 
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circumstances provision should be made for iron chelation therapy. 
1. 3. 2 Acquired Aplastic Anaemia 
Acquired aplasia is by far the most frequent presentation and is the subject of this 
thesis. 
1. 3. 2 (a) Drug Induced Aplastic Anaemia 
Drugs are a well known cause of marrow failure and in some instances such as the 
myelosuppression associated with cancer therapy, this is predictable. However, 
many other chemicals have also been implicated in bone marrow toxicity as a side 
effect, but because this occurrence is infrequent, cause and effect have been 
difficult to demonstrate (Roberts, 1990). In others as exemplified by the antibiotic 
chloramphenicol (Yunis et al, 1980), or certain anti-thyroid preparations 
(thyouracil, methymazole) (Biswas et al, 1991) it is an undesirable toxic effect. 
This is frequently unforeseen and unrelated to dose. It can occur weeks to months 
after the drug treatment has been initiated, or even after the agent has been 
withdrawn, reflecting a genetic predisposition (Roberts et al, 1990; Kelly et al, 
1991). 
Spurred on by the potential toxicity of pharmaceutical preparations and particularly 
following the description of chloramphenicol-induced marrow damage, the 
American Medical Association Council on Drugs established a Sub-Committee on 
Drug Induced Blood Dyscrasias in 1955. This group had the task of giving the 
medical profession early warnings on the haematological side effects of new 
pharmaceutical products. Many such medications have been included in a list, 
although most of those described have a low occurrence for the aplastic 
complication. Nevertheless, to facilitate rapid reporting of such events, recently in 
Paris, standard designations of the various forms of drug induced cytopenias and 
criteria for causality assessment have been more clearly defined (Standardisation of 
definition and criteria of causality assessment of adverse drug reactions, 1991 ). 
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In the case of chloramphenicol, two syndromes have been described. One follows a 
dose-dependent inhibition of the bone marrow, while the other is a dose-unrelated 
irreversible aplasia. The postulated mechanisms in the former are alterations in 
mitochondrial protein synthesis, causing suppression of haem production and 
damage to cytochromes, leading to arrest of respiration and proliferation. These 
manifestations, however, are reversible upon withdrawal of the agent. 
The second clinical problem occurs in genetically predisposed individuals where 
the N02 radical undergoes metabolic reduction. Th
is reaction leads to the 
formation of highly reactive nitroso groups, which are the effectors for the 
irreversible DNA damage and lethal marrow aplasia (Yunis et al, 1980, 1984). The 
related compound Tiamfenicol, which differs chemically in the N02 radical, also 
induces a dose-dependent marrow inhibition. However, with this agent, the 
irreversible aplasia has not been reported. 
In a recent population-based case control study of patients receiving cardiovascular 
drugs conducted in Europe and Israel which surveyed a population of 23 million 
inhabitants, the risk for agranulocytosis or aplastic anaemia was found to be 
significant for propanolol (2.5), dipyridamole (3 .8), digoxin (2.5) and acetyldigoxin 
(9.9). In addition, excess toxicities were also found with cinepazide, procainamide 
and furosemide (Kelly et al, 1991). 
Irreversible idiosyncratic reactions to carbamazepine, although rare, have been 
increasingly reported. This has resulted in specific warnings and recommendations 
from the manufacturer for regular monitoring of the haematological parameters in 
those receiving this therapy. Leukopenia has been described in 7% of adults and 
12% of children, but has often reversed despite continuation of the drug (Wyllie & 
Wyllie, 1991 , Sobotka et al, 1990). Those with initial low leukocyte counts appear 
to carry the highest risk (Sobotka et al, 1990). 
Among the anti-inflamatory medications, similar reactions were reported following 
phenylbutazone intake, leading to restriction in its use. Nevertheless, despite 
attempts to produce safer preparations, blood discrasias were described in 
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association with nearly every antirheumatic agents, including diclofenac (Eustace et 
al, 1989), ticlopidine (Pioda et al, 1989), naproxene (Sanal & Gur-Lavi, 1992), D-
penicillamine (Fishel et al, 1989). However, when scientific epidemiological 
principles were applied in the reporting of some of these agents, a significant rise in 
the incidence of blood discrasias could not be confirmed (Imperiale & Horwitz, 
1989). 
Benzene, used as a solvent in industry for more than 50 years, has been 
inconsistently implicated in cases of marrow aplasia (Paci et al, 1989; Aksoy, 
1989). Although this chemical has been consistently classified as non-mutagenic on 
the Ames test, it has also been shown to cause pancytopenia and significant 
cytogenetic abnormalities in laboratory animals (Kissling & Speck, 1972). 
The metabolism is complex, yielding glucuronide and sulphated conjugates of 
phenol, quinol and catechol, L-phenylmercaptopuric acid and muconaldehide. 
Quinol is oxidized to p-benzoquinone. This compound binds to vital cellular 
components or undergoes redox cycling to generate oxygen radicals. 
Muconaldehides are also toxic through depletion of intracellular glutathione. The 
formation of oxygen radicals by the described steps, appears to be the major 
mechanism of benzene toxicity. However, other pathways including synergism 
between arylation and glutathione depletion that lead to the creation of more 
reactive oxygen radicals, may also become operative. These reactions lead to 
suppression of DNA synthesis or chromosomal breaks (Yardley-Jones et al, 1991). 
In the industry, safety regulations by the US Government initially limited the 
atmospheric exposure of benzene to 10 parts per million (ppm) (Elkins & Pagnata, 
1956), but recently this was lowered to 5 ppm and to 1 ppm in the United 
Kingdom. 
However a number of related chemicals used as household cleaners or in the 
general industry have also been associated with this toxicity including toluene, the 
insecticides DDT (Sanchez-Medal et al, 1963, Rugman & Cosstick, 1990), lindane 
(Rauch et al, 1990) and others. Despite extended experience, the long term-safety 
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of organochlorines remains doubtful, as they were introduced before adequate 
toxicological screening tests had been developed. 
Nevertheless, despite careful history taking, in more than 50% of patients, none of 
the drugs or chemicals commonly associated with aplasia can be elicited (Haak, 
1978, Novitzky et al, 1991 b). This may follow the general perception that certain 
medications purchased over the counter, cosmetics and hair or other dyes are not 
considered as drugs and often not remembered. 
This and other susceptibilities have been linked to specific HLA types. In this 
regard the association of aplastic anaemia and HLA phenotype has been 
investigated by several researchers. Although pilot studies suggested such an 
interaction, in larger series, no excess frequencies for any antigen or haplotypes 
were found (Albert et al, 1976, Haak, 1978). 
1. 3. 2 (b) Radiation Damage to the Bone Marrow 
Ionizing X-rays, gamma rays or neutron radiation m sufficient doses cause 
molecular changes with formation of ions, peroxides and free radicals, which in 
turn may transfer the absorbed energy to critical macromolecules, leading to cell 
death (Borel et al, 1965 ). 
In the marrow, all haematopoietic elements are highly sensitive to this form of 
energy. Long-term continuous exposure to small amounts of external or internally 
deposited radiation have been followed by aplastic anaemia, which may develop 
even months or years after exposure (Court-Brown & Doell 1957). 
1. 3. 2 (c) Aplasia Induced by Viral Infections 
Viruses have also been extensively implicated in bone marrow failure (Rosenfeld & 
Young 1991). Post hepatitis aplasia is typically caused by the C virus, an organism 
similar to the flaviridiae, a family of microbes of known cytopathic effects on the 
myeloid organ. Onset of aplasia occurs while jaundice and other manifestations are 
resolving, with an incidence of0.1-0.2% ofthose infected, representing 2.5 - 8.7% 
of cases of aplastic anaemia. With a lower frequency, both hepatitis A and B have 
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similarly been implicated, although with the latter, coexistence with the C virus 
further complicates the etiologic interpretations. 
However, as some patients with active hepatitis and marrow aplasia may lack the 
described serological or hepatic tissue viral markers, a distinct non-A, non-B, non-
e organism which induces a CD 8+ lymphocytosis is increasingly being imputed 
(Hibbs et al, 1992). 
In a similar fashion, Dengue virus, Cytomegalovirus, Epstein Bar, B 19 parvovirus 
and HIV (Human Immunodeficiency) are now part of a growing list of other 
probable infectious agents with similar damaging potential on the marrow cells 
(Rosenfeld & Young, 1991). 
Duncan's Syndrome is an X-linked recessive lymphoproliferation where subjects 
are unable to mount an efficient immune response to the Epstein-Barr virus, 
leading to a spectrum of disorders which include aplastic anaerrua, 
hypogammaglobulinemia and malignancies (Schuster et al, 1991 ). The specific 
pathogenetic mechanisms resulting in marrow failure are unknown, although direct 
cytopathic effects have been proposed. These may include, as for CMV, loss of 
relevant genetic sequences for crucial haemopoietic growth factors (Simmons et al, 
1990). Alternatively, as suggested by the response to immunosuppressives 
(Frickhofen et al, 1991 ), or the presence of extensive lymphoid infiltrates in the 
bone marrow (Te Velde & Haak, 1977) a distortion of the immunological response 
directed against the viral proteins may mediate the destruction of the myeloid 
elements (Bierman & Nelson, 1965). 
1. 3. 2 (d) Paroxysmal Nocturnal Haemoglobinuria (PNH) 
Paroxysmal nocturnal haemoglobinuria is a clonal disorder characterized by 
abnormalities in the glycosylphosphatidyl-inositol-linked proteins (GPI) (Rosse 
1990, Rotoli & Luzzatto, 1989). This results in enhanced sensitivity to 
complement and haemolysis. Investigations into the haematopoiesis in this disease 
have also revealed variable degrees of pancytopenia including typical aplasia and 
leukaemia. 
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In the bone marrow cells, several biochemical and kinetic alterations have been 
reported. GPI linked molecules include multiple proteins that control the cell 
interactions with complement such as decay accelerating factor (DAF or CD 55), 
membrane inhibitor of reactive lysis (MIRL or CD 59), and C8 binding protein. 
These sequences regulate on the cell membrane, the dynamics of proteins 
belonging to the complement system. Abnormalities at this level result in 
unrestrained cell lysis (Hilmen et al, 1992). Similarly, GPI anchors the lymphocyte 
function antigen-3 (LFA-3 or CD 58) to cellular membranes. This recognition 
molecule for cytotoxic lymphocytes is also deficient in PNH. During the initial 
immunological aggression that results in bone marrow failure, loss of these 
receptors may give a survival advantage to these clones. On the other hand, loss of 
these molecules may also lead to decreased recognition by natural killer (NK) cells 
of abnormally transformed clones and to leukaemic transformation. 
There is agreement that PNH derives from the expansion of an abnormal 
population which develops through a somatic mutation. In most patients it persists 
in equilibrium with the normal haematopoiesis, while in others it virtually replaces 
the normal myeloid tissue (Young, 1992). In vitro bone marrow cultures have 
demonstrated a reduction in the number of clonogenic progenitors, giving further 
support for this close relation with aplasia. Clinically these patients suffer from 
chronic haemolytic anaemia often associated with recurrent episodes of nocturnal 
abdominal pain and exacerbation of the haemolytic state with haemoglobinuria. A 
thrombophilic state has also been described, with a significantly higher incidence in 
arterial and venous thrombotic episodes (Rotoli & Luzzatto, 1989). 
Bone marrow aplasia can be the initiating event or, following immunosuppressive 
therapy, appear with recovery of the haematopoiesis. This clonal proliferation 
replaces the normal myeloid tissue, resulting in clinical haemolysis and a positive 
Ham's test. Alternatively, this cell membrane disorder may develop as a primary 
process (Young, 1992). 
1. 3. 2 (e) Aplastic Anaemia Associated to Pregnancy 
The first description of aplastic anaemia was in a pregnant female (Erlich, 1888). 
Since then, many case reports and some series have been published recently 
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(Aitchson et al, 1989, van Besien et al, 1991) exemplifying the problem. 
Aplasia increases the risk for both the mother and the foetus due to anaerma, 
related toxemia and bleeding. Furthermore, pregnancy often worsens the 
haematological picture of aplasia while delivery may lead to recovery. If the 
decision is to carry the pregnancy to term, close observation of the mother and the 
foetus is recommended. Although the mechanisms of the bone marrow damage 
remain unclear, hormonal imbalances or unidentified foetal proteins appear to 
interact with the haematopoietic stem cell or the immune system of the mother. 
1. 3. 3 Epidemiological Studies in Aplastic Anaemia 
Aplastic anaemia is a relatively infrequent disorder. Although the specific incidence 
in Africa is unknown, series in Europe, the Far East and the Americas suggest a 
yearly occurrence ranging from 1. 5 to 13 new cases per million inhabitants (Hine et 
al, 1990, Mary et al, 1991 , Bottiger & Westerholm, 1972, Bottiger & Bottinger, 
1981 , Szklo et al, 1985). Frequency appears to be higher and severity greater 
among young adults. 
Third World countries seem particularly affected, as evidenced by data from the 
Orient (Young et al, 1986). However figures in Thailand and China appear to 
resemble more the European data (Yang & Zhang, 1991 , Issaragrisil et al, 1991). 
The reasons for these marked differences are unclear, although environmental 
factors such as the more liberal use of chloramphenicol-containing 
pharmaceuticals, or poor control in the manipulation of toxic insecticides or 
pesticides that have been implicated in the disease, are postulated. Nevertheless, 
the generally low frequency of this disorder means that large series can only be 
compiled over a long time and that controlled clinical trials can only be performed 
by large centres or cooperative groups. 
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1. 3. 4 Bone Marrow Failure. Clinical Features 
The clinical presentation in aplasia is heterogeneous, and depends on the severity 
of the disease. There appear to be at least two categories, a larger group with a 
very high initial mortality, where patients die at a rate of 20% per month following 
diagnosis and those patients where long-term survival is possible with a lowered 
risk of death to approximately 2% monthly (Nathan, 1984). This wide clinical 
variability can therefore lead to conflicting conclusions during the analysis of small 
therapeutic trials. 
Presentation, however, is often insidious. Patients are usually referred at late stages 
of the disease, when the complications of the pancytopenia have become clinically 
obvious with weakness and fatigue from the anaemia, neutropenic fever or 
fulminant septicaemia and a bleeding tendency as a consequence of 
thrombocytopenia. Occasionally intermittent menorrhagia or epistaxis persuade 
patients to seek professional advice earlier. 
Physical examination is frequently unremarkable except for pallor, purpura and 
petechial bleeding, with local or systemic manifestations of infection such as 
tachycardia and bounding pulses. The presence of splenomegaly or significant 
lymphadenopathy on presentation is unusual and more often suggestive of a 
lymphoproliferative disorder. 
1. 3. 5 Bone Marrow Failure. Laboratory Findings 
By definition, in aplasia, pancytopenia is a universal finding. It may, however, be of 
variable intensity. Anaemia is typically normocytic or macrocytic (Marsh et al, 
1987, Novitzky et al, 1991), with a low corrected reticulocyte count. The 
leukocyte count is also reduced, with a granulocytopenia often below 1 x 109/L, 
absolute lymphopenia with inverted CD4/CD8 ratios and sometimes a relative 
monocytosis. Monocytopenia which is seen in two thirds of patients carries a more 
severe prognosis. In a similar manner the platelet count is decreased, in direct 
relation to clinical bleeding. 
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Based on the severity of the hematological picture, it has become customary to 
divide this disease according to the presentation peripheral blood values into 
hypoplasia, severe aplastic anaemia (SAA) (Camitta & Thomas 1978) (Table N° 
1.1) and more recently very severe aplasia (VSAA) (granulocytes <0.2 x 109/L, 
and platelets <10 x 109/L) (Marsh et al, 1987). 
TABLE N° 1. 1 
SEVERE ACUTE APLASTIC ANEMIA (DIAGNOSTIC CRITERIA) 
1. -Reticulocytes <l % (corrected for Hct. ) 
Granulocytes <0.5 xl09/L 
Platelets < 20 xl09/L 
2.-Bone marrow cellularity < 25% of normal or 25-50% 
with > 70% non-haematopoietic tissue. 
(Camitta et al 1978) 
The value of this division resides in allowing an improved selection of patients for 
therapy, as those with the more severe forms are unlikely to respond to supportive 
management or androgenic steroids (Camitta & Thomas, 1978). Here, if a 
phenotypically HLA identical sibling is available, bone marrow transplantation 
remains the treatment of choice. 
Typically, peripheral blood morphology shows a normocytic picture, but there is 
often evidence of macrocytosis of the red cells (Marsh et al, 1987) with some 
megaloblastic features being frequently described. Granulocytes are scanty, and 
may show features of dysplasia. Morphology of the bone marrow aspirates may 
range from absent particles and scanty cells in the trails, to variable fat replacement 
and reduction in all series, while iron stores are typically preserved. 
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Trephine biopsy confirms hypoplasia, often showing frank absence of any 
haematopoietic elements. In a proportion of patients, inflammatory changes that 
include lymphocytes and macrophages have been described. Although it was 
initially suggested that patients with this lymphohistiocytic infiltrate may represent 
a more favorable prognostic group (Te Velde & Haak, 1977), this observation has 
not been subsequently confirmed (de Planque et al, 1989). 
F errokinetic studies show a significant delay in the clearance and negligible 
utilization of the isotope 59fe (Williams et al, 1985). Moreover, for the same 
concentration of haemoglobin, erythropoietin blood levels and 24 hours urinary 
excretion rates often exceed those found in most other types of anaemia that are 
due to production defects (Bray et al, 1992, Takeichei et al, 1988). These findings 
are explained by a reduction in the utilization of the hormone by the remaining 
bone marrow elements. 
1. 3. 6 Aplastic Anaemia. Therapy 
Initial retrospective clinical studies suggested that treatment with androgenic and 
adreno-corticoid steroids could lead to an appropriate stimulation of the 
haematopoiesis (Sanchez Medal et al, 1969). However, controlled trials 
demonstrated that when aplasia was severe, they were ineffective (Camitta & 
Thomas, 1978). From these studies, based on the presentation blood values and 
bone marrow picture selection criteria were proposed, where more intensive 
modalities such as bone marrow transplantation should be explored (Table 1, page 
13) (Camitta & Thomas, 1978). 
On admission, management requires a balance in the risks and benefits between the 
initial supportive approach and the hazards of curative therapies. In the severe 
subgroup, if a suitable donor is available, bone marrow transplantation has become 
the therapy of choice (Storb et al, 1991). However the outcome may become 
compromised by initial sensitization with transfusions of blood products which are 
aimed at a symptomatic relief only. On the other hand profound pancytopenia may 
cause the patient to be at an excessive risk of death from bleeding or severe 
anaemia. Nevertheless, aggressive initial therapy of infections with specific or 
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broad spectrum antibiotic combinations together with avoidance of medications 
that interfere with platelet function are beyond debate. However, since only about 
one quarter of individuals may have a suitable donor, alternative therapeutic 
options are needed. Based on the observation that immune mechanisms may 
suppress haematopoiesis (Cline & Golde, 1978) and in some patients despite 
intensive preparative regimens, autologous reconstitution may follow unsuccessful 
bone marrow allografting (Territo, 1977), a number of clinical trials have examined 
the role of immunomodulating agents. Various schedules of high-dose 
corticosteroids (Marmont et al, 1983, Kitamura & Urabe, 1989, Lopez-Karpovich 
et al, 1991), cyclosporine A (Stryckmans et al, 1984) anti lymphocyte globulin 
(Marsh et al, 1987, Novitzky et al, 1991) or monoclonal antibodies (Doney et al, 
1985) have been reported with variable outcomes. 
Prednisone alone may result in transfusion independence in 20 to 32% of patients 
(Marmont et al, 1983, Kitamura et al, 1989), leaving for more intensive modalities 
to those primarily unresponsive to corticosteroids. This approach, however, leads 
to a delay in the delivery of an effective treatment for the majority. 
Anti-lymphocyte globulin has been widely used as an immunosuppressive in the 
prevention and treatment of rejection of solid organ transplantation. It also appears 
effective in reversing the pancytopenia of marrow aplasia in the majority of the 
patients treated (Speck et al, 1986, Novitzky et al, 1991 , Novitzky & Jacobs, 1992 
[c]) . 
The mechanism of action remains to be elucidated, as monoclonal antibodies raised 
against T lymphocytes were ineffective in inducing a similar clinical response 
(Doney et al, 1985). The combined actions of both immunosuppressive and other 
modulating properties on the accessory cell populations of the bone marrow are 
therefore postulated (Gascon & Scala, 1988, Nimer et al, 1991). Despite clinical 
responses and improvement in the haematology, blood counts normalise in only 
one third of the patients, while recurrence of the disease occurs in another 20% 
(Novitzky et al, 1991 [b ]). Nevertheless, despite subnormal blood values, 
responding subjects are able to lead normal lives and enjoy a good performance 
status (Novitzky et al, 1992 [b]) . 
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Following the discovery of cyclosporine, a fungal undecapeptide with selective 
action on lymphocytes derived from the thymus (Borel et al, 77), several groups 
studied the effects of this immunosuppressive in severe aplasia. After initial 
encouraging results (Totterman et al, 1989), recent controlled studies have 
confirmed the effectiveness of this agent in untreated patients (Esperou et al, 
1989), even in those initially unresponsive to ALG (Hinterberger-Fischer et al, 
1989) or after clinical relapse (Novitzky, unpublished observations). Furthermore, 
when employed in combination with ALG and corticosteroids, it seemed 
particularly effective in the very severe variety of the disease (Frickhofen et al, 
1991). 
Nevertheless, in responding patients, after extended follow up, morphological and 
functional derangements of the mature blood elements have been described, with 
features similar to those reported in patients with myelodysplastic syndromes and 
pre-leukaemia. Other patients may display excessive sensitivity to complement as 
demonstrated by a positive Ham's test, and develop clinical evidence of PNH ( de 
Planque et al, 1988, Novitzky et al, 1992 b ). Furthermore, a proportion seems to 
transform to acute leukaemia, and this risk of developing clonal disorders appears 
to increase with time (Tichelli et al, 1988). This indicates that, either the marrow 
was repopulated by unstable progenitor cells with a high potential for clonal 
progression, or that the originating insult persisted chronically, leading to the 
described morphological and functional derangements, thus also explaining the 
prevailing risk of relapse. 
1. 4 PATHOPHYSIOLOGY: INTERACTIONS BETWEEN THE 
HAEMA TOPOIETIC STEM CELL AND THE BONE MARROW 
MICROENVIRONMENT IN APLASTIC ANAEMIA. SEED OR 
SOIL? 
1. 4. 1 Normal Haematopoiesis 
1. 4. 1 (a).- Introduction. Normal Bone Marrow Function 
It has been postulated since 1906 (Carnot & Deflandre) and proven m 1950 
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(Reissman, 1950, Erslev, 1953) that erythropoiesis is under the control of a 
humoral factor, later named Erythropoietin. The hunt for the corresponding 
"granulopoietins" took another three decades. In the 1960's Pluznik and Bradley 
(Pluznik et al, 1965, Bradley & Metcalf, 1966) developed techniques for the 
growth of bone marrow cells in vitro as colonies. These clonogenic assays have 
become useful tools and allowed further research into the cell interactions and their 
growth requirements of the bone marrow progenitors. Initial studies suggested that 
the organization of the haematopoiesis was hierarchical, where mature cells arise 
from multipotent precursors or stem cells, via intermediate precursors (Metcalf & 
Moore 1971). 
These concepts were confirmed by radio biological experiments in the 1940s and 
provided evidence that these myeloid progenitors could also reconstitute a lethally 
irradiated animal, forming early multipotent colonies first in the spleen (CFU-S) 
and later repopulating the bone marrow (Till & McCullock, 1964). 
Initially, these in vitro clonogenic assays employed agar, methyl-cellulose or fibrin 
clots (Metcalf 1977) as cell supportive structures and required supernatants of 
epithelial, leukocyte (Iscove et al, 1971) or fibroblastic cultures (Burguess et al, 
1977). These conditioned media contained survival factors that stimulated growth 
and differentiation of bone marrow cells. Chemical purification of the extracts 
(Burgess et al 1987, Miyake et al, 1977, Stanley & Guilbert, 1981 , Nicola et al, 
1983) led to sequencing, genetic definition (Jacobs et al, 1985) and eventually the 
synthesis of these haematopoietic growth factors by the recombinant technology 
(Egrie et al, 1986, Wong et al, 1985). 
1. 4. 1. (b) Haematopoietic Growth Factors 
Proliferation of eukaryotic cells is controlled by a series of regulatory events that 
include the expression and redistribution of enzymes and other proteins associated 
with DNA synthesis occurring during the G 1 phase of the cell cycle (Pardee, 
1989). Colony Stimulating Factors (CSF) act mainly on the myeloid cell lines as 
survival determinants, leading to expansion and terminal differentiation of the 
progenitor cell pool. Growth factors and other cytokines regulate these 
proliferative events through specific receptors located on cell membranes (Jones & 
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Millar, 1989). These stimulating proteins lead to the activation of the signaling 
pathways in the nucleus, necessary for cell division (Pouyssegur & Seuwen, 1992). 
Erythropoietin (Epo) is a 39 Kd glycoprotein produced by the peritubular cells of 
-the kidney and its secretion appears to be controlled by tissue oxygen saturation 
(Spivak, 1992). However, bone marrow macrophages also contain m-RNA for 
Epo, although their contribution to erythropoiesis still remains unclear (Wang, et al 
1992). This hormone stimulates committed erythroid progenitors to initiate 
division and differentiation. However, optimal clonal expansion is only achieved in 
the presence of other potentiating molecule(s), loosely termed as Burst-Promoting 
Activity (BPA). 
Interleukin 3 (IL-3) a 20 Kd molecule is a multi CSF that stimulates all the myeloid 
cell lines, and is also the main source for erythroid BPA (Saeland et al, 1988). 
Together with granulocyte-macrophage (GM), granulocyte (G) and macrophage 
(M) CSF acts on the myeloid progenitors enhancing their function and terminal 
differentiation (Jones & Millar, 1989). 
Cells of the monocyte/macrophage lineage are among the most prominent sources 
of G-CSF, but this factor can also be produced by endothelial, fibroblastic and 
mesothelial cells. Its secretion can be stimulated by endotoxin, IL-1 , tumor 
necrosis factor (TNF), GM-CSF, IL-3, IL-4 and interferon gamma (INF-y) 
(Demetri & Griffin, 1991). Through high and low affinity receptors on target cells 
this cytokine stimulates mainly the myeloid lineage, with neutrophils possessing the 
highest receptor density. Additionally, it also interacts with early multipotent 
precursors directly or through accessory cell populations with synergistic 
properties with IL-3 and GM-CSF. 
GM-CSF was the first cytokine to be cloned in this group. The gene is situated on 
chromosome 5 (5q21-q32), not far apart from the genes for IL-3 , IL-4, IL-5, M-
CSF and its receptor (c-fms). It is secreted by T cells, mast cells, macrophages, 
endothelial cells and fibroblasts that have been activated during an immune 
response or by monokines such as IL- I and TNF. It also interacts with high and 
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low affinity receptors on membranes of multipotent and lineage restricted target 
cells (BFU-e in combination with erythropoietin and CFU-gm). It primes 
neutrophils enhancing their ability to respond to triggering stimuli for super oxide 
generation and phagocytosis, but inhibits the migration of polymorphs (Gasson, 
1991). 
Stem cell factor (SCF) is the product of the steel locus (S) and is the ligand for the 
c-kit proto-oncogene tyrosine kinase receptor, encoded by the white spotting (W) 
locus of the mouse. Mutations at the SI and W loci have been associated with 
developmental disturbances and haematopoietic defects which include macrocytic 
anaemia and mast cell deficiency (Zebo et al, 1990 a and b ). This cytokine is a 
multipotent factor that acts on cells of the myeloid, mast cell and lymphoid 
lineages, with synergistic properties with IL-7, Epo and other CSF, on multipotent 
and lineage restricted progenitors. 
It is reasonably clear now that in the haemopoietin family of GF (IL-3 , G-CSF, 
GM-CSF, and Epo), interaction between receptors and their ligands leads to 
activation of phospholipase C, formation of diacylglycerol and inositol triphosphate 
resulting in intracellular Ca++ release and in activation of calmodulin. This calcium 
binding protein is reported to regulate cyclic nucleotides (c-AMP, c-GMP) and 
protein phosphorylation that are crucial for the growth-factor-dependent transition 
of cells from G 1 to S phase (Evans et al, 1987). 
Alternatively, the tyrosine kinase type of receptors transduce signals for another 
variety of growth factors . These include Epidermoid GF, Transforming GF a , 
platelet derived GF, CSF-1 , insulin, c-kit ligand etc. They possess a large 
extracellular ligand binding domain, a single hydrophobic transmembrane segment 
and a cytoplasmic portion that contains the tyrosine kinase catalytic domain. Upon 
activation, following tyrosine auto-phosphorylation, oligomerization of the 
receptor occurs leading to the activation of intracellular second messenger proteins 
such as phosphoinositol 3 kinase and phospholipase C resulting in the proliferative 
responses (Pouyssegur & Seuwen, 1992). 
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It is, however, possible that convergence and synergy of these signals between 
both pathways exist, leading to stronger mitogenic responses from cooperative 
signals (Pouyssegur & Seuwen, 1992), relayed through switch kinases such as 
mitogen activated protein-kinases (MAP-kinases) in kinase-kinase cascades (Payne 
et al, 1991 ) . In this area, knowledge is incomplete, and interest in the definition of 
the controlling sequences for cell division is keenly shared not only by cell 
biologists but also by clinicians dealing with disorders such as aplastic anaemia and 
leukaemias. 
1. 4. 1. (c).- Organization of the Haematopoietic System 
Haematopoietic stem cells (HSC) are considered to possess an extensive capacity 
to give rise to new stem cells (self-renewal) and generate progenitors that are 
committed to expression in single lineages ( differentiation) . This process of self-
renewal and differentiation continues throughout the life-span of the subject, with 
little evidence for "ageing" of the system. 
Based on the analysis of frequency distribution of spleen-colony-forming units 
(CFU-S), it was concluded that the replication of the HSC follows a stochastic 
model (Till & McCulloch, 1964). Furthermore, the regulation of this compartment 
may be achieved by changes in the distributional parameter for the probability of 
self-renewal (Humphries et al, 1981 ). Moreover, commitment also seems to follow 
a progressive and stochastic restriction in cell lineages (Suda et al, 1983). 
Multipotent progenitors differentiate in semisolid cultures (Johnson & Metcalf, 
1977, Hara & Ogawa, 1978, Fauser & Messner, 1979) in the absence of a 
structurally intact microenvironment, suggesting that bone marrow or splenic 
stroma are not important for stem-cell commitment. However, the long-term 
maintenance of CFU-S has been reported only in the presence of myeloid stromal 
monolayers (Gartner & Kaplan, 1981). This suggests a crucial supporting role of 
the bone marrow microenvironment in the self-renewal of the HSC. 
Indefinite serial re-transplantation is not possible. After 4-5 repopulations it 
eventually leads to HSC depletion with bone marrow failure (Cudkowitz et al, 
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1982) and this is not the result of stromal injury (Gardner et al, 1988). Although 
haemopoiesis is maintained through a massive amplification, stem cell replicating 
potential is finite as originally indicated by the "clonal succession" model (Kay, 
1965), where "founder cells" have the greatest capacity only while they have not 
entered into cell cycle. However, once cells divide, they will increasingly develop a 
more limited proliferative aptitude and become exhausted (Botnick et al, 1982). 
Clinical experience and animal studies confirm that late haemopoietic failure has 
been noticed long after radiation exposure (Seed & Kaspar, 1990). When 
reproduced in vitro, this reduction in culture life was unrelated to radiation damage 
to stromal cells but associated with a decline of the number ofHSC. This limitation 
in the repopulation potential seems more intense in blood derived progenitors than 
spleen or marrow derived CFU-S. This indicates that there is a clear role for the 
stroma in protecting "sternness", and resulted in the term "haematopoietic niches" 
(Tavassoli & Crosby, 1968; Schofield et al, 1978). 
Following marrow transplantation, founder cells freed from this stromal protection 
will be lost into differentiation, while clonal succession ensures repopulation of the 
HSC pool and will project cells that have divided, even closer into commitment. 
Further support for the "niche" model has come from long-term bone marrow 
cultures (LTBMC) (Dexter et al, 1984). In this novel approach, bone marrow 
stroma is allowed to become confluent with the concomitant production of early 
myeloid progenitors. 
In this system, CFU-S in the stromal layer (SL) appear to have a similar clonogenic 
capacity to that of normal bone marrow resident cells, while within the 
supernatant, among the non-adherent progenitor this is greatly reduced (Dexter et 
al, 1984). Furthermore, transfer of the stroma residing precursors onto another 
fresh SL decreases markedly its proliferative capacity (Moore and Dexter, 1978, 
Schofield et al, 1980) in secondary cultures, mimicking this the in vivo experience. 
In vitro, the LTBMC proved to be the most physiological of myeloid culture 
assays (Gartner & Kaplan 1981) where haematopoietic progenitors proliferate and 
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differentiate in close contact with the stromal population for many weeks. Here, a 
marked diversity in the cell population forming the marrow stroma is observed 
(Castro-Malaspina et al, 1980). 
Once confluent monolayers are formed, fibroblasts, endothelial cells, monocytes, 
blanket cells, adventitial reticular cells and their progeny the fat cells (Bianco et al, 
1988) form a tight structure where populations of the immune system such as the 
B lymphocytes (McGuinnes et al, 1991) and those of the T lineage (Shibata et al, 
1986) are well represented. 
In this assay, haemopoietic output seems to be the product of a balance between 
growth factors and negative regulators or "restrictins" (Zipori & Tamir, 1989). 
Among the GF identified in the SL granulocyte (G), macrophage (M) and 
granulocyte-macrophage (GM) CSF, tumor necrosis factor alpha (TNFa), IL-1 , 
IL-4, IL-5, IL-6, IL-7 (Zipori & Tamir, 1989, Mc Guines et al, 1991 , Gualtieri et 
al, 1984, Gualtieri et al, 1987) and c-kit ligand are included, as well as them-RNA 
for IL-3. These findings have been confirmed by the inhibition of the clonogenic 
development of growth factor (GF) dependent cell lines in the presence of target 
GF neutralizing antibodies (Kittler et al, 1992). 
In the stroma, non-haemopoietic cells also secrete a variety of products that form 
an extra cellular matrix (ECM). These are broadly divided into three categories: 
collagen, proteoglycans and glycoproteins. Fibroblasts are associated with 
granulopoiesis; in co-culture they seem to control myeloid proliferation (Nagao et 
al, 1986) and secrete type III collagen. Blanket cells produce fibrinectin and 
laminin while endothelial cells produce type I and IV collagen. 
Glycosaminoglycans (GAGs) which interact with cellular adhesion molecules on 
cell membranes, also bind soluble haematopoietic growth factors making them 
directly available to progenitor cells (Gordon et al, 1987 b, Gordon, 1991). This 
would explain the low concentrations of some of these GF found in the culture 
supernatants and why clonogenic growth is maintained despite the addition of anti-
CSF antibodies to LTBMC (Lipschitz et al, 1987). Further, confirmation of their 
importance in growth regulation is exemplified by a significant reduction in the 
HSC output, upon inhibition of collagen secretion by cis-hydroxyproline (Campbell 
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et al, 1988). 
Through specific membrane cell adhesion molecules (CAM) as CD 44 (Lewinsohn 
et al, 1990, Tsai et al, 1987, Vuillet-Gaugler et al, 1990) or CD 54 (Arkin et al, 
1991) respectively, immature erythroid precursors and granulocytic progenitors are 
anchored to the polypeptides fibrinectin and haemonectin. This adhesiveness 
appears to be down regulated and lost upon differentiation, allowing cells to be 
released into the culture supernatant, or in vivo, to the circulation (Tsai et al, 
1987). 
This culture method has been tested m a variety of haematopoietic diseases, 
including myeloproliferative disorders (Hotta et al, 1986), acute and chronic 
leukaemias (Verfaille et al, 1992) as well as in bone marrow aplasia (Boyd et al, 
1986, Marsh et al, 1990) providing reproducible data. 
A modification of this system has been described, where monocyte depleted 
myeloid progenitors are incubated on preformed bone marrow stroma and allowed 
to adhere, then immobilized with agar and scored for the development of 4-
hydroperoxycyclophosphamide resistant blastic colonies (Gordon et al, 1985). 
These stroma-adhesive progenitors also form secondary colornes, with a 
repopulating potential similar to umbilical cord precursors (Nakahata et al, 1982). 
In this assay, the adhesive properties of the earliest clonogenic cells, their growth 
potential as well as the growth-promoting properties of the stroma are tested 
without the need of external GF supplementation. 
1. 4. 2.- Haematopoiesis in Aplastic Anaemia 
In aplastic anaemia the data remain incomplete and are often conflicting. These 
results reflect the diversity in both the clinical expression of the disease and in the 
different research techniques employed by the investigators. However, more 
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recently certain new concepts have helped clarify some of these issues. 
With standard culture techniques, employing various conditioned media, semi-solid 
clonogenic assays of the bone marrow indicated a significant reduction in the 
clonable progenitors (Haak, 1978). This reduction was seen even in those 
responding to immunosuppression or androgenic steroids, despite normalization of 
the peripheral blood counts. These findings contrast with the experience from 
those undergoing bone marrow transplantation, where in vitro colony formation 
recovered after the procedure (Haak, 1978). To explain such findings, quantitative 
(Heimpel & Kubanek, 1975) or qualitative abnormalities (Heimpel & Kubanek, 
1975, Boggs and Boggs, 1976) of the progenitor cell compartment have been 
postulated in patients treated with immunomodulation. 
Alternatively, and based on in vitro observations of cell-mediated inhibition of the 
myeloid and erythroid progenitors by a population with growth suppressor 
properties (Ascensao et al, 1976, Gorski et al, 1979, et al, 1980), an 
immunological down regulation of clonogenic growth was postulated. This was 
confirmed by reports that T-lymphocytes with the E+ Fey+ OKT3+ Ia- OKMl-
phenotype or a soluble factor from their conditioned medium could mediate this 
inhibition (Bacigalupo et al, 1984, Viale et al, 1991). Although control bone 
marrow also contained immunocytes that belonged to such a population and 
displayed similar suppressor activities, this required pre-activation with lectins, 
which in patients with aplasia, was found to be spontaneous. Of interest, in another 
subgroup of patients expressing similar autoreactive CD4+/CD8+ lymphocytes, 
monoclonality of this population was documented by gene rearrangement studies 
for the Beta chain of the T cell receptor, (Moebius et al, 1991). 
Further research into the immune system in these patients on presentation or in 
those that responded to ALG, confirmed that lymphoid cells collected and 
cryopreserved before therapy and later exposed, in co-cultures, to autologous 
marrow obtained after response to immunosuppression, in a dose dependent 
fashion inhibited CFU-GM proliferation. This was reversed by anti-interferon 
gamma (INF-y) antibodies. Here again, effector cells were identified as CD 8+ and 
this activity was reversed by immunosuppressive therapy with ALG (Laver et al, 
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1988). 
Although controversial, in aplasia, serum INF-y levels appear not to be increased 
(Torok-Storb et al, 1987). Unexpectedly, excessive secretion of this cytokine was 
demonstrated from peripheral blood and bone marrow lymphocytes in these 
patients (Zoumbos et al, 1985), even before becoming sensitized by transfusions 
with blood products (Hintenberger et al, 1988). Nevertheless, pre-incubation of 
the bone marrow progenitors with anti-INF-y antibodies did not improve colony 
formation . Although, when exposed to incremental concentrations of ALG, GM-
CSF secretion was induced in a linear pattern by these bone marrow accessory 
cells present in the culture (Hintenberger et al, 1988). 
Cells of the immune system are an active part of the bone marrow stroma 
(McGuinnes et al, 1991 , Shibata et al, 1986), producing a variety of positive and 
negative cell function regulating cytokines (Pantel & Nakeff, 1989). In aplasia, 
experimental data have shown that INF-y and TNFa. are secreted excessively by 
bone marrow cells, spontaneously or after exposure to mitogens (Bacigalupo et al, 
1984, Zoumbos et al, 1985, Hintenberger et al, 1988, Viale et al, 1991). Both 
these cytokines are known to exert antiproliferative effects on myeloid precursors 
(Tracey et al, 1989). Although this inhibition was reversed by specific neutralising 
antibodies (Zoumbos et al, 1985), in untreated subjects, excessive production was 
again indirectly suggested by enhanced neopterin secretion, which reversed after 
the infusion of ALG (Hinterberger et al, 1988). 
Clinically, equine anti-lymphocyte globulin appears to have a equivalent effect to 
these neutralizing antibodies (Platanias et al, 1985, Tong et al, 1989). Moreover it 
seems to induce the release of various haemopoietic growth factors (Nimer et al, 
1991) and to exert antiproliferative effects on B lymphocytes (Bonnefoy-Berard et 
al, 1992). 
Of similar interest is that monocytes that are widely represented in the stroma, have 
also been found to be deranged, with alterations in surface membrane 
glycoproteins, their development to macrophages impaired (Andreesen et al, 
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1989). These findings persisted despite successful ALG therapy. Furthermore, in a 
subsequent study in untreated patients, IL-1 production was also significantly 
reduced (Gascon & Scala 1988, Nakao et al, 1989), while clinical response to 
horse immunoglobulin led to recovery in the secretion of this cytokine (Gascon & 
Scala 1988). It was therefore not surprising that inhibition of erythroid bursts 
(BFU-E) has also been reported when these adherent mononuclear cells were 
cocultured with normal or patient myeloid progenitors (Torok-Storb et al, 1980, 
Merchav et al, 1988). 
Macrophages form an integral part of the bone marrow microenvironment and are 
a source of both haematopoietic growth factors and inhibitory proteins (Feldman et 
al, 1986). Therefore, functional alterations in this population may lead to 
subnormal progenitor cell stimulation. Alternatively, damage to the HSC pool can 
be manifested as derangements in these mature elements. Indeed, there is a 
considerable volume of data documenting morphological and functional 
abnormalities of all the differentiated haemopoietic progeny, including 
granulocytes, erythrocytes, platelets (de Planque et al, 1989 [a] and Chapter 2) and 
B lymphocytes (Lum et al, 1987). Furthermore, development of PNH in aplastic 
anemia is well documented (Rotoli & Luzzatto 1989, Rosse, 1982, Rosse, 1990), 
as well as transformations to other clonal disorders such as myelodysplastic 
syndromes and acute leukaemias (Tichelli et al, 1988, Orlandi et al, 1988, de 
Planque et al, 1988). 
However, following the description that in this disease one half of syngeneic bone 
marrow transplants are unsuccessful without preconditioning (Appelbaum et al, 
1980) and the evidence provided by the Steel (Sl!Sld) murine congenital anaemic 
model where the myeloid microenvironment is abnormal (Dexter & Moore, 1977, 
Anklesaria et al, 1991 ), research was also directed to the marrow stoma. Results of 
stromal cultures showed derangements in the adherent layer, with fibroblasts 
displaying atypical growth in multiple layers (Juneja et al, 1984). Contrary to 
normal, in some patients these failed to support CFU-gm (Hotta et al, 1985). Here, 
of further interest, the expression of genes for INF-y in myeloid mononuclear cells 
appeared to predict for a favorable outcome in those treated with cyclosporine 
(Nakao et al, 1992). 
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To investigate this controversy further, based on the LTBMC assay, Marsh 
employed confluent irradiated stroma from patients responsive to ALG treatment 
and compared their behaviour to control stroma. She concluded that the aplastic 
layers did not differ morphologically from normal and in their ability to sustain 
normal haematopoiesis. 
However, although care was taken to seed predominantly with haematopoietic 
progenitors, rigorous selection for this population was not attempted, allowing 
normal bone marrow accessory cells, including those of the immune system to 
"engraft" and interact with the aplastic stroma. This has confused somewhat the 
final conclusions with regard to the aplastic stromal integrity (Marsh et al, 1990). 
In a follow-up study, selected myeloid precursors for the CD 34+ antigen from 
patients with aplasia were compared to controls in cross culture experiments on 
normal and aplastic stroma. Here, it was demonstrated that in the patients, 
progenitors were markedly decreased in numbers and had a significantly lower 
plating efficiency, therefore suggesting that the defect resided predominantly within 
the haemopoietic stem cell compartment (Marsh et al, 1991). This writer has also 
reached the same conclusions, in a similar patient population, employing the blastic 
colony assay (Gordon et al, 1987 b) with CD 34+ selected progenitors on aplastic 
and control stroma. Furthermore, when equal numbers of CD 34 + cells from 
patients with treated aplasia were exposed to rh-GM-CSF or IL-3 in the presence 
of erythropoietin, the plating efficiency was decreased 10 fold compared to 
controls (Novitzky et al, 1991). A mechanism for this sub-optimal response was 
not apparent. 
1. 4. 3 Rationale for the Study and Concluding Remarks 
The experimental data reviewed, indicate that an initial aggression to the myeloid 
tissues as a result of either alterations in the immune system or within the bone 
marrow microenvironrnent lead to a marked depletion of the haematopoietic 
precursors and to clinical bone marrow failure . However, contrary to the 
experience with intensive chemotherapy or radiotherapy, a spontaneous recovery 
fails to follow this initial injury. 
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The objectives of the present study were to define more clearly the net effect of the 
bone marrow stroma in down-regulating the normal proliferative signals in aplastic 
anaemia. Initially, bone marrow stromal layers from patients with aplasia and from 
controls were cultured in vitro and studied morphologically, cytochemically and in 
their ability to support the growth of myeloid progenitors. One problem identified, 
was that light density mononuclear populations of the marrow that contained the 
earliest progenitors and expressing the CD 34 antigen were also contaminated by 
multiple accessory cells with regulatory functions . To avoid these interactions, 
positive selection for these precursor cells was undertaken allowing a more clear 
comparison of the clonogenic potential between the diseased and the normal 
marrows, when grown in cross-culture on control or aplastic stroma. 
The limitations of this methodology become clear during the pilot study as, due to 
the low selected progenitor cell yields obtained in the untreated patients, more 
comprehensive studies on the HSC could not be performed. With the clear 
understanding that the pathological processes might not be similar to those 
occurring during the initial presentation, this analysis was then confined to 
individuals that had responded to the immunosuppressive therapy. Here, as already 
described, despite the normalization of the blood values, morphological and 
functional derangements in the blood elements persisted and were associated with 
a significant reduction in the clonogenic progenitors. 
If these initial observations confirmed abnormalities in the stem cell population, in 
a second step, these selected progenitors would be exposed to increasing 
concentrations of appropriate combinations of recombinant growth factors, and 
their clonogenic responses compared to the results obtained in a normal group. 
In this thesis, firstly, a review of the clinical and laboratory data of patients with 
aplastic anaemia attending the Department of haematology at Groote Schuur 
Hospital is presented in Chapter 2. Here, the haematopoiesis of subjects who had 
responded to immunosuppressive treatments was defined by a systematic 
morphological, cytogenetic and functional study of the various blood elements. In 
Chapter 3 a description of the selection techniques employed for the CD 34+ 
population is given and two different methods compared. In Chapter 4 a pilot 
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study is described, where normal and aplastic stroma are compared in their ability 
to support CFU-bl, the CD 34+ populations quantitated and cultured in vitro in the 
presence of recombinant growth factors . 
In Chapter 5 a detailed description of the normal and aplastic bone marrow stroma 
is presented, and an analysis of the interactions of the adherent layers with the 
selected CD 34+ adherent and non-adhesive progenitors discussed. Here, it 
becomes clear that the aplastic stroma does not suppress normal colony formation 
and that the clonogenic defect resides within the HSC. Following this logical 
sequence, selected normal and aplastic haematopoietic cells were exposed to 
growth factors belonging to the two super-families of receptors and results are 
presented in Chapter 6. Lastly, in Chapter 7 a summary of the findings is presented 
and the final conclusions discussed. 
CHAYfER2 
QUALITATIVE ABNORMALITIES CHARACTERISE 
HAEMATOPOIESIS THAT RESTORES MARROW 
FUNCTION FOLLOWING THERAPY WITH 
ANTILYMPHOCYTE GLOBULIN (ALG) AND HIGH DOSE 
METHYL PREDNISOLONE (HDMP) IN APLASTIC 
ANAEMIA 
2. 1 INTRODUCTION 
Aplastic anaemia is characterized by irreversible bone marrow failure, resulting 
in profound pancytopenia (Camitta & Thomas, 1978). Although the causes of 
this syndrome are largely unknown, some of the described associations include 
recent exposure to certain drugs (Appelbaum et al, 1981), pregnancy (Aitchison 
et al, 1989; Van Besien et al, 1991), jaundice (Hagler et al, 1975 , Rosenfeld et 
al, 1991) and atypical viral infections such as Dengue and Parvovirus 
(Rosenfeld, 1991). 
The clinical expression is variable , reflecting the intensity of the haematopoietic 
damage , ranging from mild or moderate hypoplasia responsive to androgenic 
steroids (Sanchez Medal et al , 1969), to severe aplasia where this hormonal 
therapy has been of no benefit (Camitta & Thomas, 1978). In contrast, 
allogeneic bone marrow transplantation improves survival , particularly in 
younger patients (Storb et al , 1983), and those who have not been sensitised by 
previous transfusions or pregnancy (Anasetti et al , 1986). However, only the 
minority will have a suitable donor. 
Based on the observations that immune mechanisms may suppress 
haematopoiesis (Cline & Golde, 1978), anti-lymphocyte globulin (ALG) and 
cyclosporine, alone or in combination with corticosteroids, have been employed 
with responses in over 50% of patients (Speck et al , 1986, Esperou et al, 1989, 
Novitzky et al, 1991). Extended follow-up has demonstrated that relapses may 
occur. In others, despite adequate recovery or even normal peripheral blood 
values, variable degrees of dysplasia occur (de Planque et al , 1989 band c), and 
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platelet functions are deranged (de Planque et al , 1989 a) , with alterations in T-
lymphocyte subsets as well as reduction in the serum immunoglobulins (Lum et 
al, 1987). 
These findings are reminiscent of some of the abnormalities described in 
myelodysplastic syndromes. These observations apply particularly in the 
subgroup that presents with hypoplastic bone marrow and improves following 
appropriate immunosuppressive therapy (Tichelli et al, 1988 [ c ]), making 
reliable separation from aplasia difficult. Compounding this complexity, a 
subgroup of patients with marrow aplasia may evolve not only to paroxysmal 
nocturnal haemoglobinuria and acute leukaemias, but also to myelodysplastic 
syndromes (Tichelli et al , 1988 [a and b]). 
To address this issue we have studied a cohort of patients that presented with 
typical features of severe aplasia and received a uniform immunosuppressive 
treatment. We have attempted to define the morphologic , cytogenetic and 
functional characteristics of their haematopoiesis and to describe these 
abnormalities that have persisted even after eight years following therapy. 
2. 2 STUDY PATIENT POPULATION 
From January 1985 to December 1991 , 34 individuals, with severe aplastic 
anaemia (Camitta & Thomas, 1978), 15 of whom have been previously reported 
(Novitzky et al , 1991) and one with hypoplasia, were referred for therapy . 
Their median age was 25 ,5 years (range 13-72; SD 15.66) and 17 were female. 
Only one had a donor suitable for allogeneic bone marrow transplantation. Two 
had convalescent serology for hepatitis B, one was pregnant and recovered 
partially following therapeutic abortion . One was exposed to chloramphenicol in 
eye drops and another received chlorquine for rheumatoid arthritis and neither 
recovered after drug discontinuation. 
On presentation, the median values for haemoglobin (Hb) were 66 g/L (SD 
20 .9) , the reticulocyte count 0.3% (SD 0 .29) , mean red cell volume 102 fL (SD 
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54.76), granulocyte count 0.50 x 1Q9/L (SD 0.44) and platelets 11.5 x 109/L 
(SD 5. 7). All had normal serum B12 and red cell folate levels. For this group, 
the median bone marrow cellularity was 15% (SD 5.4) of normal. 
2. 2. Aplastic Anaemia. Therapy 
All patients received uniform supportive care that included leukocyte poor 
packed red cells, allogeneic platelets transfusions and appropriate antibiotics. 
After the diagnosis had been confirmed, subjects were entered into a standard 
protocol with ALG and high dose-methyl prednisolone (HDMP), approved by 
the University of Cape Town and Groote Schuur Hospital Ethics and Research 
Committees. The treatment consisted of ALG (horse immunoglobulin without 
thrombocyte adsorption; Swiss Serum Institute , Bern , Switzerland) 50 mg/kg 
and HDMP 500 mg daily on each of five consecutive days , followed by 30 mg 
daily of prednisone for one month (Novitzky et al, 1991). 
Patients were assessed at six months and again one year after therapy . Response 
was defined as reversal of symptoms, freedom from transfusions , a stable rise in 
the platelet count above 40 x 1Q9 /L and an absolute granulocyte count greater 
than 1 x 1Q9 / L. Complete remission required Hb greater than 120 g/L, 
granulocytes > 2.5 x 1Q9/ L and platelets of > 150 x 109/ L. Patients with 
inadequate responses or with fluctuating blood counts received oxymetholone 
two mg/kg for six to nine months with careful monitoring of the liver functions. 
2. 2. 2 Laboratory Investigations 
2. 2. 2. (a) Morphological Assessment of the Haematopoiesis in Aplastic 
Anaemia. 
Peripheral blood 
Complete blood counts, red cell indices, platelet size and distribution width 
were generated on a Technicon Hl Analyzer (Tarrytown, New York) . 
Peripheral blood slides were stained with May-Grunewald-Giemsa (Lewis et al , 
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1986) and differential counts derived manually. Complement sensitivity of red 
cells was determined by sucrose lysis and acidified tests. 
Bone Marrow Examination 
Aspirates were air-dried and morphology was defined on slides stained with 
Romanowsky dyes (Lewis et al, 1986). Iron content was determined in 
normoblasts and reticuloendothelial cells with a special search for pathological 
inclusions, ringed sideroblasts or the presence of dysplastic features according to 
the French-American-British criteria (Bennett et al , 1982). 
Trephine biopsies were obtained with the Jamshidi needle (Bird & Jacobs 1983), 
processed, sectioned and stained with haematoxilin and eosin and evaluated for 
inflammatory infiltrates, abnormalities in the stroma or abnormal localization of 
immature precursors (ALIP) (Mangi et al , 1992). 
2. 2. 2. (b) Cytogenetics Studies of the Bone Marrow in Patients with 
Aplastic Anaemia 
Bone marrow was collected into RPMI containing 20% foetal calf serum 
(Gibco, UK) and heparin (Novo, Nordisk; Johannesburg, 100 U/mL) . 
Chromosome analysis was performed on trypsin (Dice Michigan, USA) giemsa 
banded metaphases obtained from direct harvest or methotrexate (0.5 µg/mL; 
Lederle) synchronisation of bone marrow cells. When necessary , cytogenetics 
on phytohaemagglutinin (PHA) (Gibco , Grand Island NY) stimulated peripheral 
blood cultures were also carried out to establish the constitutional cell line. 
2. 2. 2.(c) Granulocyte Functions in Patients with Aplastic Anaemia 
Peripheral blood leukocytes were obtained from thirteen patients with aplastic 
anaemia and from nine concurrent controls by Dextran sedimentation (Dextran 
6% w/v in 0.9% Na Cl) of heparinized blood (20 U/mL) and divided in aliquots 
for the various functional tests. 
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Superoxide Generation 
Determination of super oxide generation was done following a previously 
described method (Markert et al, 1984). Patient and control leukocytes were 
washed at 4 ° C in RPMI, re-suspended in PBS, and maintained at 4 ° C. To 1Q6 
cells, 0.01 mL of distilled water (reference control) or super oxide desmutase 
(Sigma St. Louis; 4200 U/mg, 0.4 mg/mL) (test sample) was added. The 
sample was incubated at 37° C for 2 minutes followed by the rapid addition of 
0.05 mL horse heart cytochrome C (30 mg/mL MG Ca 12500, Boehringer-
Mannheim W. Germany) and then of pre-warmed phorbol myristate acetate 0.75 
mL (Sigma, 1 µg/mL) , followed by another ten minutes' incubation at 37° C 
under continuous rotation, when the reaction was stopped by rapid cooling on 
ice. Cells were then washed at 4 ° C, cytochrome reduction measured in a 
double beam spectrophotometer at 550 11m, and super oxide generation 
calculated by the formula: 
0 2- ('riM/L) = 47.7 x absorption 02· 
0 2" ('riM/min/106 cells) 
S: sample 
R: reference 
(S- R) 47.7 
~~~~~~~~~~~+10 
cell concentration factor x 10 
47. 7: extinction coefficient 
Phagocytosis and Killing 
The combined measurement for phagocytosis and killing (Yamamura et al, 
1977) was determined on the buffy (1 x 1Q6/mL) suspended in 0.5 mL of 
medium containing 20% serum (Western Province Blood Transfusion Service 
WPBTS, Cape, S. Africa) . Leukocytes were mixed in triplicates with 6 x 
1Q6/mL Candida Albicans organisms and incubated at 37° C under constant 
rotation for 30 minutes. Tubes containing 20% serum and C. Albicans or cells 
alone were used as controls. 
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For the quantitation of phagocytosis, aliquots with 0.1 mL of the cell suspension 
were added to wells containing 0.2 µCi of 3H-uridine (Amersham). For the 
killing assay, polymorphs were also incubated for 30 minutes in 1.2 g Na 
deoxycholate (Hopkin & Williams, Essex; UK) in 0.01 mL distilled water 
containing 5 µg DNAase (Sigma, bovine pancreas). Radioactivity in the 
suspension was collected onto glass fibre disks with a cell harvester (Skatron 
Titertek, AS-3401 LIER, Norway), placed in scintillation fluid and counted in a 
scintillation spectrometer (Beckman LS 1801 , USA). 
Phagocytosis (PI) and killing indices (Kl) were calculated as : 
CPM Candida + PMN · CPM PMN 
100 -------------- X 100 
CPM Candida alone 
(The proportion of C . Albicans killed can be determined by: Kl.;. PI x 100) 
Migration and Chemotaxis 
Chemotaxis was studied according to Addison with slight modifications 
(Addison, 1976). Using Luckham Lp3 tubes (Luckham, Sussex; UK) 0.4 mL 
normal or aplastic neutrophils (2 x 106/mL) were placed on cellulose nitrate 3 
µm filters (Sartorius 25G, type 70) prewarmed to 37° C, wet in autologous 
plasma or RPMI + Hepes (control) for random migration or f-MLP 10-8 M 
(Sigma Pharmaceuticals, Missouri, USA) for chemotaxis. These were then 
placed on Whatman's N° 54 filter paper, soaked in appropriate medium, 
incubated at 37° C for 30 minutes , rinsed in water, fixed in propan 2-ol for five 
minutes, stained with Harris haematoxylin and the migration distance read on a 
Leitz microscope. 
2. 2. 2. (d) Lymphocyte Functions and Serum Immunoglobulin Levels 
Peripheral blood mononuclear cells from patients with aplasia and controls were 
obtained from a 1.077 g/mL density gradient (Hystopaque, Sigma). Cells were 
washed twice in RPMI (Sigma) and 0.1 mL of the suspension at a concentration 
of 5 x 105 /mL were cultured for three days at 37° C in 96 well microtiter plates 
(Cel-Cult, Sterilin Ltd. Hounslow UK) in the presence of 0.05 mL of 
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concavalin A (Calbiochem La Jolla Ca, USA), phytohemagglutinin, pokeweed 
mitogen (Gibco) or heat inactivated AB serum (WPBTS). Cells were then pulsed 
with 1 µCi 3H-Thymidine (Amersham, 1:200) at 37° C, harvested eighteen 
hours later on to dry filter discs and the radioactivity counted. 
For the mixed lymphocyte reaction, stimulating allogeneic control lymphocytes 
were thawed, their viability determined by trypan blue exclusion, and incubated 
at 37° C for 20 minutes in mitomycin (Sigma, Mo 0503; 1:8 dilution). After 
being washed twice in medium, 0.1 mL of the cell suspension (5 x 105/mL) was 
cultured in triplicates with patient or control lymphocytes for five days and 
pulsed with 1 µCi 3H Thymidine (Amersham) for 18 hours. Cells were then 
harvested on to filter discs and radioactivity was measured on a Beta scintillation 
counter (Beckman). 
Immunoglobulin levels were evaluated by agar electrophoresis. Quantification of 
IgG, IgA and IgM was performed by single radial immunodiffusion using 
immunodiffusion plates and compared to a normal range (Fahey et al , 1965). 
2. 2. 2. (e) Determination of the Platelet Functions in Aplastic Anaemia 
Bleeding Time and Platelet Aggregometry 
Platelet functional activity was determined only on patients with platelet counts 
> 100 x 109 /L (n=14) and compared to controls. Both groups were instructed 
to avoid medications that could interfere with platelet function for two weeks 
preceding the study. Bleeding time was determined by the Ivy method, and at 
the same time blood was collected for aggregometry into siliconised vacutainer 
tubes containing sodium citrate. Comparisons were carried out in platelet-rich 
plasma, using a Chronolog aggregometer with results registered on a chart 
recorder (Chronolog Corporation Haverton Pennsylvania; model 560vs and 
model 707). 
The system was calibrated using platelet-poor or rich plasma at 100% and 0% 
respectively. Measurements were taken at the maximum point of the 
aggregation. These were expressed as per cent variation in light transmission 
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compared with baseline values in response to adenosine diphosphate (ADP 
Sigma, Missouri) at final concentrations of 100, 10 and 5 µg/mL , (0.2-0.01 
mMol), collagen (Sigma) at a concentration of 2 µg/mL, ristocetin 1.5 mg/mL 
(Sigma) and epinephrine (May Baker, South Africa) 0.01 mM. 
2. 2. 3 Statistical Analysis 
Patient survival was measured by Kaplan-Meier. Median values and confidence 
intervals (confidence coefficient: .95) of the patient results were obtained, 
compared with control results and significances tested by two-way analysis of 
median values. 
2. 3 RESULTS OF THE CLINICAL, MORPHOLOGICAL AND 
FUNCTIONAL STUDIES PERFORMED ON THE BLOOD 
ELEMENTS IN APLASTIC ANAEMIA 
2. 3.1 Response To Therapy and Long-Term Follow Up 
The patient with hypoplasia remitted after a therapeutic abortion, and as she was 
not treated , was excluded from analysis of response to therapy. For the entire 
group, the median time from initial symptoms of pancytopenia to therapy was 
sixty days (SD 94.3) . Response was seen in 24 of the 34 subjects (71 % ), and 
this was complete in eight. At a median follow-up of 1320 days (SD 803) 22 
(65 %) are alive in response (Fig N° 2. 1, page 38). One patient required two 
courses. He is currently in complete remission. Five patients developed immune 
complex disease following the ALG infusion, and in one plasma exchange was 
needed to reverse the intense vasculitis. In the remainder, an increment of the 
prednisone dose to 1 mg/kg was sufficient to control these manifestations within 
two weeks. Although haematological response was seen at a median of 110 days 
(60-300), improvement in the blood counts continued for up to four years after 
therapy. Six of 24 patients (25 %) relapsed. In one, disease recurred at 180 days. 
This patient subsequently died of sepsis and pulmonary embolization shortly 
after receiving a second course . Another reached response criteria values, but 
relapsed sixty days later . As she had a compatible sibling, she underwent T cell 
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depleted (CAMPATH lM) allogeneic bone marrow transplantation, but failed to 
engraft and died at 270 days . One female relapsed at 620 days in the third 
trimester of her second pregnancy . She was supported until term and improved 
her blood counts following the delivery of a normal infant. Three patients 
required further immunosuppression, and are on their second (one patient) or 
third response (two patients). In one, cyclosporine maintenance is necessary for 
a sustained response. 
Patients who had responded were re-evaluated at one year when their Kamovsky 
rating was 100% (Table N°2. 2, page 41). Median Hb was 115.0 g/L (SD 
25 .3) , MCV 102 fL (SD 9.51), Granulocytes 1. 7 x lQ9/L (SD 1.65) and 
platelets 88 x 109 /L (SD 80.0). None of the presentation clinical findings 
including sex, age , length of aplasia, or development of immune complex 
disease were predictive for response. Among the pre-treatment laboratory 
findings , only a raised MCV was significantly associated with response 
(responders , median 109 fL, SD 10.1 vs non-responders 91 fL, SD 7 .6, median 

























DAYS FOLLOWING THERAPY 
Fig N° 2. 1: Follow up of patients with acute aplasia treated with 
ALG+HDMP. 
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2. 3. 2 Study Patient Population (Table N° 2. 2) 
Of 22 patients alive in response after immunosuppressive therapy and one 
following therapeutic abortion, sixteen were available and agreed to undergo the 
present study (Table N° 2. 1 and 2. 2; pages 40 and 41). On presentation, all 
fulfilled the diagnostic criteria for severe aplasia (Camitta & Thomas, 1978). 
Morphology in thirteen patients revealed mild megaloblastosis limited to the red 
cell precursors, while in another, in addition mild dysplasia in the granulocytic 
series with giant bands was also observed. Morphology was entirely normal in 
one, and in two patients there were no analyzable haematopoietic tissue. 
Reassessment of 16 patients belonging to this group was performed at a median 
of four years from therapy (range 1-8). The median haemoglobin was 134.5 g/L 
(SD 27.2) , MCV 98 fL (SD 7.17) , Granulocytes 2.21 x 109/L (SD 1.89), 
lymphocytes of 1.53 x 1Q9/L (SD 0.71) , monocytes of 0.23 x 109/L (SD 0.18) 
and platelets 127 x 109/L (SD 80.44). Two patients developed a positive Ham's 
test with clinical features of PNH. Another four had increased sucrose 
haemolysis , but on blood chemistry and serological testing showed no evidence 
of intravascular red cell destruction (Table N° 2. 2 , page 41). 
2. 3. 2.(a) Morphological Assessment of the Haematopoiesis in Patients with 
Aplastic Anaemia (Table 2. 3) 
Morphology was entirely normal in three subjects only. On the peripheral 
blood, erythrocyte dysplasia (mainly as megaloblastic morphology) was present 
in 11 patients, while in six it also affected the granylocytic series(in the form of 
hypersegmentation or Pelger-Huet neutrophils). In the bone marrow, 
megaloblastic erythroid maturation was present in 13 patients. It was 
accompanied by myeloid dysplasia in 8 with additional megakarycytic dysplastic 
morphology in 3. Iron stores were absent in one patient while pathological or 
ringed sideroblasts were not seen in any . No excess of blasts, inflamatory 
infiltrates or increase in mast cells were seen. On the biopsy, median cellularity 
was 40%. Morphologically , tri-lineage dysplasia with abnormal localization of 
immature precursors (ALIP) was present in 3 patients, and in two, a patchy 
increase in reticulin fibrosis was observed (Table 2.3 , page 42) . 
TABLE2.1 
POST - ACUTE APLASTIC ANAEMIA 
Mean 
Patient Haemoglobin Corpuscular Granulocytes Platelets FoUowup Observations 
g/L Volume xx 109/L x 109/L Years 
No Age Sex fL 
1 42 F 134 85 2 .10 103 4.5 Response N°2 
2 48 F 91 115 2.59 28 5.2 On CSA 
3 18 M 128 106 2 .13 100 1.3 On CSA 
4 68 F 136 107 1.48 136 3 .6 
5 32 F 135 100 1.98 111 1.0 Post-abortion 
6 32 F 143 94 1.57 176 5 .4 
7 48 M 144 94 5 .76 181 5.0 
8 47 F 137 94 2 .62 159 6 .3 
9 19 F 117 99 1.76 216 5.0 Hepatitis 
10 36 F 85 103 2.30 102 6.4 PNH 
11 28 M 84 98 0 .75 29 4.9 Relapsed x 3 
12 24 M 163 98 5 .08 180 5.2 ALGx 2 
13 47 F 123 90 4 .04 375 4 .1 Quinine tox . 
14 29 M 66 103 1 .77 118 7 .7 PNH 
15 25 M 139 98 2 .92 116 4.0 
16 29 M 145 95 1.63 143 5.2 Hepatitis 
Description of the study population and the haematological parameters. CSA: Cyclosporin A 
therapy. 
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Due to the lack of features of bone marrow failure , none fulfilled the diagnostic 
criteria for myelodysplasia (Bennett 1982). 
2. 3. 2. (b) Cytogenetic studies 
Metaphases suitable for analysis were obtained in fifteen of sixteen individuals. 
One patient had an abnormal karyotype expressed as 4 7, XX + C in eight of 
twelve metaphases, and the remainder showed random chromosomal loss. PHA 
stimulated peripheral blood analysis confirmed the constitutional nature of the 
trisomy X. Chromosomal breaks and or gaps were present in five of fifteen 
patients, ranging from 13 to 40% of cells tested . No other cytogenetic 
abnormality was detected. 
2. 3. 2. (c) Results of the Granulocyte Function Studies {Table N° 2. 3) 
Only one patient of thirteen had normal granulocyte functions ; in three all 
assays were deranged. In the remaining subjects results were below control 
values in at least one assay. As a group these were significantly reduced for 
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super oxide generation (p= 0.007) and phagocytosis (p= 0.002). Variations in 
migration and killing were present in eleven patients, but for the group these did 
not reach significance (Table N° 2. 4, page 44) . No correlation was found 
between blood leukocyte counts and in vitro granulocyte functions , or any other 





Peripheral One year Four years 
Blood 
Median Standard Median Standard 
(n= 16) Deviation Deviation 
Haemoglobin g/L 115.00 25.30 134.50 27 .21 
Granulocytes x 1o9 /L 1.70 1.65 2.21 1.89 
Lymphocytes x 109 /L 0.92 1.65 1.53 0 .72 
Monocytes x 109 /L 0.15 0.12 0.23 0.18 
Platelets x 109 /L 88.00 80.00 127.00 80.44 
Peripheral blood values of the study population with aplastic anaemia evaluated at 1 and 4 
years following ALG therapy. 
3. 2. 2 (d) Results of Lymphocyte Function Studies and Serum 
Immunoglobulin Levels 
All measurements were normal in twelve patients, but subnormal in both 
patients on cyclosporine therapy . Serum immunoglobulins were determined in 
fourteen subjects and values were found within normal range in all, including 
both patients on maintenance immunosuppression. 
2. 3. 2. (e) Functional Studies of the Platelets. Results 
Bleeding Time 
The platelet count was greater than 100 x 1Q9/L (median 127; SD 80.44 x 
1Q9/L) in fourteen patients. However the Ivy time was normal in only five of 
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the individuals. For all patients the median bleeding time was 8.5 minutes (SD 
3.4) (laboratory normal range 3-7 minutes), and in three was greater than fifteen 
minutes. 
< 
TABLE 2. 3 
MORPHOLOGICAL EVALUATION 
Bone Marrow Number 
Morphology of 




One lineage 2 
Two lineage 6 
Three lineage 5 
Megaloblastosis 
One lineage 4 
Two lineage 6 
Three lineage 2 
Abnormal localization of immature 
precursors (ALIP) 3 
The bone marrow was studied in patients with aplastic 
anaemia at 4 years following ALG therapy. 
Platelet Aggregation Studies. Results (Table N° 2. 5) 
Aggregation studies were abnormal in all patients and this derangement applied 
to each of the agonists tested with significantly sub-optimal values for ADP 100 
µg (p= 0.001); 10 µg (p= 0.0012); 5 µg (p= 0.08), Adrenaline (p= 0.001), 
Collagen (p= 0.003) and Ristocetin (p= 0.0002) (Table N° 2. 5, page 45). 
2. 4.- DISCUSSION OF THE FINDINGS 
This study confirms the effectiveness of anti-lymphocyte globulin in reversing 
the haematological abnormalities associated with severe aplasia . The response-
rate and long-term survival of 71 % and 65% respectively are consistent with 
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other reports (Speck et al, 1986). However, when the various therapeutic 
options are examined, several points must be considered. Selection in the patient 
population, differences in the schedules employed (Doney et al, 1992, O:zsoylu 
et al, 1984) as well as variability in the biological product (Novitzk:y et al , 
1991, Smith et al, 1985) may all lead to fluctuations in the results reported. 
Young children (Locasciulli et al , 1990) and patients with the very severe 
variety (Marsh et al , 1987, Gluckman et al , 1992) have lower response rates, 
and this should be a clear consideration when entertaining therapeutic 
alternatives such as matched unrelated donors for this high-risk population 
(Hows, 1991). 
Retrospective studies indicate that dosage of horse immunoglobulin may be of 
importance, with consistently higher response rates when values over 100 mg/kg 
are infused (Coiffier et al, 1984). In vitro , results appear to correlate clinical 
response to proliferation of lymphocyte subsets (Abe et al , 1991) and the release 
of CSF (Kawano et al , 1988), when these cells are exposed to ALG in culture, 
following a clear dose response (Tong et al , 1991). Clinically , more intense 
therapeutic schedules may combine profound immunosuppression with activation 
of the various growth factors in vivo , balancing in favor of stem cell recovery 
(Kawano et al, 1988, Tong et al, 1991). 
Endorsements for this hypothesis are the results of recent controlled trials 
showing that, while corticosteroids with cyclosporine or ALG appear of similar 
therapeutic potency (Doney et al, 1992), significantly better responses were 
obtained when cyclosporine was added to ALG with steroids (Frickhofften et al, 
1992), which in the very severe group resulted in a significant survival 
advantage. 
Presentation macrocytosis was the only feature significantly associated with 
Favourable response to this therapeutic regimen (Marsh et al , 1987, Novitzk:y et 
al , 1991). However, mild megaloblastic changes progressed to widespread 
dysplasia, increased deposition of reticulin and even abnormal localisation of 
immature precursors over the follow up-period. Nevertheless, in no case did this 
progress meet the diagnostic criteria for myelodysplasia (Bennett et al, 1982). 
FUNCTIONS 
TESTED 




TABLE 2. 4 
GRANULOCYTE FUNCTIONS 
PATIENTS (n = 12) 
Median Standard Number 
Deviation of Pa ents 
Abnormal 
2.79** 0.60 4 
83.00 33.97 7 
65.00 17.38 10 
Phagocytosis (Percentage) 53.10** 12.89 1 
Killing (Percentage) 32.00 18.61 7 
* p <0.05 
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Functional study of the plymorph leukocytes of patients with aplastic anaemia tested at a 
median of 4 years following ALG therapy and compared to concurrent controls. ** denotes 
significance (p < 0.05). 
Karyotypic abnormalities may provide a clue to the possible link between aplasia 
and myelodysplasia (Appelbaum et al, 1987) and the present demonstration that 
13 to 40% of metaphases in five of fifteen individuals were abnormal , supports 
the concept that disturbed DNA repair mechanisms (Hashimoto et al , 1975, 
Turner et al, 1981) may presage evolution to the preleukaemic syndromes 
(Tichelli et al , 1988 [b ]). 
Abnormalities in the granulocyte functions have also been detected in the study 
group, with significant reduction in the generation of hydrogen peroxide and 
phagocytosis. Similar observations were described in patients with severe 
congenital neutropenia where alterations in the cellular signalling pathways 
leading to the activation of granulocyte functions had been demonstrated (Kyas 
et al, 1992; Kurtzberg et al , 1992, Roesler et al , 1992). Of note, however, is 
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that in our patients the incidence of cutaneous or systemic infections was not 
increased. 
TABLE 2. 5 
PLATELET FUNCTIONS 




ADP 100 56.00** 19.94 
ADPlO 47.50** 20.07 
ADPS 31.00 15.98 
Adrenaline 10.00** 20 .13 
Collagen 35.00** 31.70 
Ristocetin 69.50** 19.28 
** p<0.05 
Platelet Count : Median 127 (SD 80 .44) x109 /L. 





70 .00 20.94 
68 .00 25 .16 
80.00 12.74 
88.00 9.10 
Platelet aggregation studies performed on patients with aplastic anaemia at a median of 
4 years following ALG therapy. ** denotes significance (p < 0 .05) . 
However, these findings vary from another report on untreated subjects with this 
disorder, where granulocyte super oxide production was increased and further 
enhanced by in vitro incubation with GM-CSF (Oshaka et al , 1992). This 
discrepancy can be explained in that during early disease the immune system 
appears activated , with increased generation of certain cytokines such as INFy 
and TNF (Hinterberger et al, 1987, Zoumbos et al, 1985, Tong et al, 1991). 
These cytokines have been described to up modulate granulocyte responses . 
Contrary to previous reports (Lum et al , 1987), lymphocyte functions and 
immunoglobulin blood levels were uniformly normal in those not receiving 
immunosuppression. This disparity may be related to a recovery in the immune 
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system that might have occurred with time, or to differences associated with 
sample size. Nonetheless, wide variations in the immune response have been 
described in some patients, with excessive production of interferon gamma and 
tumor necrosis factor (Hinterberger et al, 1987, Zoumbos et al, 1985, Tong et 
al, 1991) and sub-optimal generation of IL-1, stressing the heterogeneity of both 
the populations studied and the methodologies employed. 
During sequential testing, despite continuous improvement in the bone marrow 
cellularity, mild thrombocytopenia has persisted in the majority . As in this 
disease, platelet survivals were previously shown to be normal (de Planque et 
al, 1989), this persistent reduction in the thrombocyte numbers is likely to 
reflect decreased production or ineffective thrombopoiesis (de Planque et al, 
1989). However , despite platelet counts exceeding 100 x 1Q9;L in fourteen, a 
value that normally is not associated with a bleeding tendency, the bleeding time 
was prolonged in seven patients, and was over fifteen minutes in three. Not 
surprisingly, all had aggregation abnormalities of variable degree and as a group 
these were significant. Similar defects have been previously described , although 
the interpretation of those results was compounded by significant 
thrombocytopenia in the population under scrutiny (de Planque et al, 1989). 
There again, however, despite improvement in the platelet values, aggregation 
studies remained subnormal. 
As the pathogenesis of the disease still remains unclear, it could be interpreted 
that the initial insult irreversibly damages the haematopoietic stem cells and this 
continues to be reflected as qualitative defects in the mature progeny. 
Alternatively, it is conceivable that the progenitor cell pool and the 
differentiating population are subject to continuous aggression by a sub-clinical 
disease within an abnormal haematopoietic microenvironment (Ershler et al, 
1980, Juneja et al , 1984, Hotta et al, 1985, Fujiwara et al , 1990). 
In conclusion, following immunosuppressive therapy for acute aplasia, even 
after a long period of quantitative recovery in the various blood elements, 
persistent chromosomic abnormalities, together with tri-lineage morphological 
and functional derangements are observed. These derangements are mainly sub-
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clinical , but due to the possibility of disease recurrence and progression towards 
clonal disorders, further research into the cellular interactions that occur within 
the bone marrow microenvironment is needed . 
CHAPTER3 
BONE MARROW PURIFICATION AND SELECTION 
FOR THE PROGENITOR CELL POPULATION. 
RESPONSE TO RECOMBINANT GROWTH FACTORS 
3. 1 INTRODUCTION 
In mature mammals, the production of the blood occurs predominantly in the bone 
marrow which is composed of heterogeneous populations of cells of 
haematopoietic origin, stromal cells and lymphoid tissue. In this environment the 
stem cell is able to regenerate its own pool, commit into the various cell lines and 
sustain a continuous output of terminally differentiated elements (Dexter 1977). 
Clonogenic assays are useful tools in the research of the proliferation and 
differentiation of haematopoietic progenitors. However, the presence of multiple 
accessory cells in the light density marrow fraction, interacting through autocrine 
loops with the various regulatory pathways controlling growth regulation of 
myeloid precursors, makes the interpretation of these assays difficult (Iscove 1971 , 
Feldman 1986). Therefore, when specifically studying the progenitor cell pool in 
disorders of the haematopoiesis, the definition of the clonogenic efficiency is as 
relevant as the exclusion from the culture system of unpredictable interactions with 
contaminating accessory cells. This situation makes the selection for the 
populations under scrutiny highly desirable. 
For this purpose, research on cell membrane surface determinants in enriched 
populations of bone marrow progenitors resulted in the identification of a 110 KD 
membrane glycoprotein present only in 1-2% of the bone marrow population, but 
in the majority of the haematopoietic precursors that form colonies in vitro . This 
membrane structure has been molecularly defined, its genetic profile sequenced 
(Xing-Yue 1992) and integrated into the Leukocyte Differentiation listing as CD 
34 (Civin 1989). The development of monoclonal antibodies against epitopes on 
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this structure resulted in the description of methodologies for the identification and 
selection of these cells to a greater purity (Greenberg 1985, Ungelstad 1987). 
Positive selection of specific cell populations has been reported with several 
techniques, including "panning" ( Greenberg 1985), immunomagnetic selection 
(Ungelstad 1987) or flow cytometry with cell sorting (Visser 1990). When these 
techniques are employed in the selection of bone marrow cells carrying the CD34 
antigen, a significant enhancement of the haematopoietic colony formation is 
observed in vitro, with marked reduction in clonogenic growth in the depleted 
fraction (Ungelstad 1987). These data and the reports of successful bone marrow 
reconstitution with grafts containing CD 34 enriched populations in humans and 
other primates (Berenson 1988, 1991 ), confirmed the hypothesis that this antigen 
was broadly represented on the membranes of the haematopoietic stem cells. 
To define the optimal methodology with regards to cell homogeneity and 
clonogenic yields, two purification techniques were compared. Additionally, the 
clonogenic behaviour of the selected population was characterised in dose 
response studies to four haematopoietic growth factors constructed in specific 
combinations. 
3. 2 METHODS FOR THE PURIFICATION AND SELECTION OF 
THE PROGENITOR CELL POPULATION. RESPONSE TO 
RECOMBINANT GROWTH FACTORS 
Bone marrow was obtained by multiple sternal aspirates from haematologically 
normal patients undergoing sternotomy under general anaesthesia for heart valve 
replacement or coronary artery cardiac by- pass surgery. All marrow donors had 
given written informed consent according to the guidelines of the Ethics 
Committee of the University of Cape Town and the Groote Schuur Hospital. 
Bone marrow rich blood was collected into 50 mL tubes containing 20 U/mL 
preservative fee heparin (Pularin, 10 U/mL; Nordisk, Johannesburg), in Iscove's 
modified Dulbecco's medium (IMDM), (Gibco Life Technologies, UK). Light 
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density cells were collected from the interface of a polysucrose diatrizoate density 
gradient (1.077 g/rnL, Hystopaque, Sigma, USA) after 30 minutes centrifugation at 
400 G at room temperature. Subsequently, cells were washed twice in medium and 
aliquots taken for morphological assessment, indirect immunofluorescence and 
quantitative determinations with an electronic particle counter (Multisizer, Culter 
Electronics, USA). 
The light density population was re-suspended in IMDM containing 2% foetal calf 
serum (FCS, Gibco, Life Technologies; UK) placed into 200 mm plastic Petri 
dishes (Bibby, UK) and incubated for two hours at 3 7° C to remove adherent cells. 
Non-plastic adhesive cells were decanted, washed twice and lymphocyte depleted 
by incubating in 15 rnL of the same medium containing 0.1 rnL CAMPATH-lM 
(6.25 mg/rnL; 0.01 rnL antibody/ 5 xI06 cells/rnL) ( 1983) for 50 minutes at 37°C 
in the presence of 3 0% AB serum as a source of complement 0N estem Province 
Blood Transfusion Service, C. Town). 
3. 2. 1 Progenitor Cell Selection 
The resulting lymphocyte and monocyte-poor progenitor cell concentrates were 
washed three times in IMDM, re-suspended in 0.2 rnL of cold (4° C) phosphate 
buffered saline (PBS) containing 0.02 rnL/107 cells of anti human CD 34 antigen 
murine monoclonal antibody (Anti HPCA-1 , My 10, Becton and Dickinson, 
Sunnyvale, California), and incubated on ice for 30 minutes. Labelled cells were 
then washed 3 times in phosphate buffered saline (PBS) containing 2% AB serum 
( complement inactivated, Western Province Blood Transfusion Service, Cape 
Town, RSA). On the labelled cells, two selection techniques were compared: 
antibody-mediated plate binding (Greenberg 1985) and immunomagnetic 
separation (Ungelstad 1987). 
3. 2. 1. (a) Progenitor Cell Antibody-Mediated Plate Binding 
(Greenberg 1986) 
Plastic petri dishes (Falcon, 75 cm2) were coated with 0.1 rnL high affinity goat 
anti-mouse polyclonal immunoglobulin (Dakopatts z 420, Denmark; 2 mg/rnL) in 
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9.9 mL of tris buffer (pH 10) for one hour at 4°C. Dishes were decanted and 
washed gently with PBS containing 2% AB serum. Labelled cells were re-
suspended into three mL of the same medium and layered on antibody coated 
dishes for 70 minutes. Non-adherent cells were washed off with PBS containing 
2% AB serum ( complement inactivated). The labelled population was then 
detached with jets of PBS and collected into 50 mL tubes, centrifuged at 400 G for 
ten minutes, counted in a haemocytometer, re-suspended in IMDM at a cell 
concentration of 1 x 105/ mL, and cultured in the mixed colony assay. Aliquots 
were also taken for trypan blue exclusion determinations, immunofluorescence, 
cytospin preparations and stained with May-Grunewald-Giemsa and a-naphthyl 
butirate esterase for morphological and cytochemical determinations. 
3. 2. 1. (b) Antibody-Coated Magnetic Bead Progenitor Cell Selection 
Polystyrene paramagnetic beads covalently bound to affinity purified goat IgG 
against all mouse IgG subclasses (M-450, prod No 125.01 , Dynal, Oslo) at a 
concentration of 5-10 beads per target cell population ( one gram of dry beads 
contains 1.4 x 1010 particles or 4 x 1 os /mL suspension, with a total surface area of 
3-5 m2) were washed four times in IMDM and exposed in continuous rotation at 
4° C to the antibody labelled population at a cell concentration of 5-10 xl09fL for 
30 minutes (Ugelstad 1987). 
Target cells were then harvested with a magnet (MPC-1 , Dynal) applied to the 
sides of the tube and free cells decanted. Incubation with the paramagnetic 
particles and magnetic separation was repeated once on decanted cells. To remove 
the magnetic beads, selected cells were re suspended in 0.1 mL of PBS containing 
0.01 mL of a polyclonal murine immunoglobulin (Detachabead, Dynal) set at room 
temperature for 60 minutes in a continuous rocking motion and exposed to the 
same magnetic conditions (Rasmussen 1992). Cells freed from spheres were 
selected, viability determined by trypan blue exclusion, counted m a 
haemocytometer and numbers adjusted to a concentration of 1-5 xl05/ mL. 
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3. 2. 2 Immunofluorescence Studies of the Selected Populations 
Aliquots of cells obtained from the initial density gradients and of the final 
separations were incubated overnight at 3 7° C in medium containing 15% FCS, 
then re-suspended, washed twice, dripped on multitest slides (Highveld 
Biologicals), air dried over 4-6 hours and frozen to -80°C for immunophenotyping, 
or employed for cytological determination after staining with Romanowsky dyes 
(Lewis 1986) and non-specific esterase. 
For immunophenotyping, frozen Multiwell slides (Highveld Biologicals, Transvaal; 
S. Africa) containing light density and selected cells were thawed and dried 
overnight, fixed in 100% acetone for 5 minutes, washed with PBS and labelled for 
45 minutes with FITC-conjugated CD3 (0.005 mL UCHT-1 Dako, Denmark), 
CD19 (0.005 mL Dako HD-37) antibodies, or CD 14 (0.01 mL CD 14, Mo 2; 
Culter; USA) and CD34 (0.01 mL Anti-HPCA, My 10, Becton Dickinson, USA) 
for indirect studies. With each case, positive (Class II antibody, Barnstable 1978) 
and negative ( directed against ~-galactosidase, Department of Clinical Sciences, 
Prof E. Dowdle, University of Cape Town) controls were always included. Where 
relevant (wells containing CD 14 and CD 34), a fluoresceine conjugated second 
rabbit antibody (Dakopatts) was added for 30 minutes. 
All excess reagents were washed with PBS, and nuclei counter-stained with 1 
µg/mL ethidium bromide for one minute, washed, mounted and read under 
ultraviolet illumination at 50 rim with a mercury gas lamp on a Nikon microscope. 
3. 2. 3 Definition of the Progenitor Cell Population. Clonogenic Assays 
3. 2. 3. (a) Growth Factors 
Recombinant human cytokines (Amgen Thousand Oaks, California); rh-IL 3 
(specific activity of 107 U/mg), rh GM-CSF, G-CSF(specific activity 1 xI08 U/mg 
respectively) and c-kit ligand, at protein concentration of 0.5, 0.5 and 2 mg/mL 
each were diluted to 103 rig/mL and kept at 4° C until used. Erythropoietin (Epo) 
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was donated by Bioclones (Sandton, Transvaal), once reconstituted kept in 2% 
FCS at 4°C and a concentration of 1000 U/mL. 
3. 2. 3. (b).Clonogenic Assays of the Selected Populations 
Positively selected CD 34 progenitors were cultured in multi-cluster dishes 
(Nunclon Delta, UK) at a cell density of 1 x 1 o4 in IMDM, containing L-
Glutamine, supplemented with 30% FCS, 5 xl0-5 2-mercaptoethanol, in the 
presence of haematopoietic growth factors in dose response studies. 
Granulocyte-Macrophage Colony-Forming Units (GM-CFUc) were defined as 
myeloid aggregates (granulocytic, monocyte-macrophage or mixed) containing 
more than 40 cells. CFU-e were described as erythroid clusters of 4-100 cells, 
while BFUe were expressed as colonies containing more than 100 cells or when 
aggregates contained three or more subclusters. 
3. 2. 3. (c) Dose Response to Growth Factor Combinations 
Further analysis of the clonogenic growth of the CD 34+ population was assessed 
in the mixed colony assay, by determining the response to incremental 
concentrations of growth factors . Six normal subjects were studied by dose 
response curves that were constructed in various concentrations for Epo (0.05, 
0.2, 2, 10 and 100 U/mL) in the presence ofIL-3 1011g/mL; GM-CSF (0.1 , 10 and 
50 11g/mL), combined with Epo 2 U/mL; IL-3 (0.05, 0.1, 1, 10 and 50 rig/mL) 
together with Epo 2 U/mL and c-kit ligand (1 , 20, 40, 100 and 200 rig/mL) in 
combination with Epo 2 U and IL-3 10 rig/mL. 
3. 3 RESULTS OF THE PROGENITOR CELL SELECTION 
AND OF THE CULTURE STUDIES 
3. 3. 1.- Progenitor Cell Selection: Morphology and Immunofluorescence 
Studies 
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3. 3. 1. (a) Selection by Antibody-Mediated Plate Binding (Table 3. 1) 
Five normal subjects were studied. Monocyte adherence, lymphocyte depletion and 
panning led to a marked enrichment for morphologically immature blast cells, from 
a median of 7% (2-13) in the light density cell fraction, to a 71% (57-88). 
Immunophenotyping of four specimens showed that 62% ( 44-76) expressed the 
CD 34 antigen, leading, therefore, to a 51 . 7 fold enrichment of this population, 
while the viability was of 72% (59-88) as determined by trypan blue exclusion. 
3. 3. 1. (b) Selection by Antibody-Coated Magnetic Beads 
Accessory cell depletion and positive selection with goat anti-mouse IgG coated 
magnetic beads also led to a significant enrichment of morphological blasts to a 
median of 85% (72-98). In 3 studies the selected population expressed 
fluorescence for CD 34 antibody in 80% (67-84) of cells. In this group none was 
reactive with non-specific esterase (Fig. N° 3. 1 and 2, page N° 55). The total 
clonogenic enrichment by this procedure was 53 .3 times and the viability, by the 
dye exclusion method, of 97% (Table 3. 1, page 56). Semi-solid cultures in the 
mixed colony assay confirmed a significant enrichment in clonogenic precursors, 
for both selection methods with increments in the numbers of erythroid (BFU-e, 
CFU-e) and myeloid (CFU-GM) colonies. Although the immunomagnetic method 
was superior, this was not significant for colony types (p > 0.05). Significantly, 
more cells taking up trypan blue were found with the panning technique (p < 0.05). 
3. 3. 2 Clonogenic Assays. Dose Response (Table 3. 2) 
Dose response studies were performed on six controls having at least three studies 
on each GF concentration. Cells selected by the immunomagnetic procedure were 
cultured at a cell concentration of 1 x l04. For Epo, increments in erythroid colony 
formation reached a plateau at 10 U/mL, while CFU-gm colonies were not 
influenced by increments in this hormone. At top concentrations macroscopic 
mixed colonies, immature BFU-e (more than seven sub colonies of blasts) as well 
as massive bursts were elicited (Fig. N° 3. 3, page 58). 
GM-CSF stimulated erythroid, myeloid and mixed colony development with 
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plateau values for BFU-e and CFU-GM colonies at 10 11g/mL. Again, macroscopic 





Fig. N° 3. 1: Immunomagnetic selection . Cells labelled with CD 34 antibody were 
magnetically selected to a median of 85 % blasts (range 72-79) (May Grunewald Giemsa; 
x 200 magnification). 
Fig. N° 3. 2 : Morphological details of the positively selected population. Occasional 
paramagnetic beads are still visible. (May Grunewald Giemsa; x 400 magnification) . 
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TABLE 3.1 
PROGENITOR CELL SELECTION COMPARATIVE STUDY 
ANTIBODY MEDIATED PLATE IMMU 0 
BIDING MAGNETIC SELECTION 
COMPARATIVE 




MORPHOLOGICAL n=5 n=5 
ASSESSMENT 
Percentage Median Ranee Median Ranee Median Ran!!e Median Ran!!e 
Blasts 7 2-13 71 57-88 8 5-17 85 72-98 
Lymphocytes 7 11-24 12 5-16 12 6-18 5 1-18 
Monocytes 7 3-17 4 1-4 9 4-10 1 1-3 
NSE 8 8-11 <2 0-2 12 4-13 0 0-1 
IMMU 0 -
FLUORESCENCE n=4 n=3 
STUDIES 
Percentage Median Ran!!e Median Ran!!e Median Range Median Ranee 
CD34 1.2 0.7-1.6 62 44-76 1.5 0.9-1.7 80 67-84 
CD3 7 1-15 <5 2-8 5 4-12 <5 0-5 
CD19 4 4-1- 7 3-7 7 5-13 5 0-7 
Cell viability 95 88-100 72 59-88 95 85-98 97 92-100 
MIXED 
COLONY n=5 n=3 n=5 
ASSAY 
Colonies 10 5 Median Ran!!e Median Ran!!e Median Ran!!e Median Ranee 
CFU-mix 13 0-19 22 12-22 0 0-2 70 10-120 
BFU-e 51 12-61 231 51-461 39 12-75 380 140-680 
CFU-e 291 231-593 1050 783-3653 72 40-133 928 260-2180 
CFU-GM 70 42-106 166 135-210 29 17-63 372 40-928 
Comparative study for the selection of CD 34+ cells between the antibody mediated plate 
binding and immunomagnetic selection. Assessment was performed on morphological, 
immuno-phenotypic and clonogenic results obtained by both methods on medians of 3 
experiments. 
Response to IL-3 was seen in all type of colonies and was maximal between 1 and 
10 rig/mL. Stem Cell Factor ( c-kit ligand) was tested in 3 normal subjects; its 
clonogenic effect favored predominantly erythroid production, with BFU-e 
numbers reaching a plateau growth between 100 and 200 rig/mL (Fig. N° 3. 4, 
page 58), while comparing to the baseline factors present (Epo and IL-3), little 
activity was detected at 1 rig/mL. 
TABLE 3. 2 
DOSE RESPONSE 
CFU-mix BFU-e CFU-e CFU-GM 
GROWTH FACTORS 
COMBINATIO S Median Range Median Range Median Range Median Range 
IL3 10T]g+ERYTHROPOIETIN 
EPO: 
O.OS U/mL 0 0 2 1-2 36 19-41 71 31-76 
0.2 U/mL 2 1-5 48 12-55 52 19-66 48 22-51 
2 U/mL 7 7-11 60 29-71 82 59-92 67 23-69 
lO U/mL 7 5-14 68 39-98 120 78-122 87 54-91 
100 0/mL 19 11-29 60 27-61 104 59-117 71 39-73 
Epo 2 U/mL + GM-CSF 
GM-CSF: 
0.1 TJglmL 0 0 21 12-29 66 21 -91 12 4-29 
1 TJglmL 0 0-3 45 19-51 86 42-105 35 21-36 
10 TJglmL 7 1-9 105 39-112 110 68-11 9 59 17-66 
SOTJg/mL 15 3-16 79 63-82 144 38-151 71 34-75 
IEpo 2U/mL+INTERLEUKIN3 
IL-3: 
O.OSTJglmL 0 0-1 19 5-22 95 39-98 16 7-22 
0.1 TJglmL 0 1-6 27 9-31 138 77-143 34 29-62 
1 TJlmL 2 1-5 67 32-75 124 79-125 29 I 1-43 
10 TJglmL 3 3-9 39 21-65 134 37-144 125 69-144 
SOTJglmL 9 3-22 57 29-97 136 98-143 113 92-166 
Epo 2 U/mL+IL-3 10 TJglmL + 
STEM CELL FACTOR 
SCF: 
1 TJglmL 0 0 40 18-51 38 33-69 6 3-16 
20TJglmL 2 2-7 61 43-75 49 37-89 21 12-49 
40TJglmL 2 2-16 99 54-119 41 32-87 26 23-69 
100 TJg/mL 9 8-19 118 68-145 38 32-69 80 27-101 
200ne/mL 2 1-16 121 77-148 39 22-57 93 22-139 
Dose response of normal selected CD 34 progenitors to combinations of growth factors 
in the mixed colony assay. Results are ex1)ressed as colonies/ 10.000 cells. 
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At optimal concentrations c-kit ligand induced massive clones of macroscopic 
bursts of mixed erythroid and myeloid growth. Immature bursts (more than seven 
subclusters, little haemoglobinization) were obvious at 100 and 200 11g/mL. 
Fig. N° 3. 3. :Morphological details of a BFU-e colony at plateau concentrations of 
growth factors (Epo 100 U/mL and IL-3 10 ng/mL), (May Grunewald Giemsa; x 100 
magnification). 
Fig. N° 3. 4: Morphological details of an immature BFU-e colony, cultured at plateau 
concentrations of c-kit ligand (Epo 2U/mL and IL-3 , 10 ng/mL). Note the immature 
appearance of the cells and lack of haemoglobinization (May Grunewald Giemsa; x 100 
Magnification) . 
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Fig. N° 3. 5: Morphological details of a mixed erythroid and myeloid colony cultured 
at plateau concentrations of GM-CSF (Epo 2 U/mL), (May Grunewald Giemsa; x 100 
magnification). 
Fig. N°3. 6: Mixed granulocytic and eosinophilic colony cultured in the presence of IL-
3 10 11g!mL and Epo 2 U/mL (May Grunewald Giemsa; x 100 Magnification). 
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3. 4 DISCUSSION OF THE RESULTS 
In humans, most bone marrow progenitors capable of forming colonies have been 
found to reside within the CD 34+ fraction. This heterogeneous population which 
represents 1-3 % (Civin 1984, 1987, 1990 ) of the marrow mononuclear cells, 
includes most of the primitive myeloid and lymphoid progenitors (Verfaille 1990), 
capable of reconstituting in vivo human and non-human primate bone marrow 
(Berenson 1988, 1991). 
As the selection for the progenitor cell was considered advantageous in the 
definition of the stem cell function in haematological disorders, it was considered 
to be of importance to develop some experience in this field, and compare two 
methods where selection techniques had been well described and no specialized 
equipment was necessary. Panning has been reported as an efficient method for 
both positive selection of specific cells, or as a complement to other purification 
procedures such as fluorescence activated cell sorting, specifically for the initial 
depletions of undesired populations (Strife 1987). 
Similarly, immunomagnetic methods have also been extensively described using 
products with wide variations in the architecture and particle sizes (Advanced 
Magnetics Boston, USA; Dynal, Oslo). In an initial pilot study paramagnetic 
particles of 1-2 µm adsorbed with high affinity goat anti-mouse IgG (Advanced 
Magnetics) were tested. Although this proved to be an efficient system, it was 
cumbersome as it required long selection times. This resulted in the decision to 
study the present magnetic spheres (Novitzky 1991 and unpublished observations). 
Dynal particles, originally developed by Ugelstad (Ugelstad 1987), consist of 
uniform polystyrene spheres of 4.5 µm in diameter with paramagnetic properties 
produced by maghaemite, dispersed throughout the volume of the bead to a final 
composition of 22% w/w. The outer surface of the particle is smooth and 
hydrophobic. It contains hydroxyl groups that can be used for the chemical 
attachment of proteins. Several techniques have been described to attach antibodies 
chemically to the bead surface, of which tosylation is the most widely used 
(Danielson 1986). 
~ . 
Fig. N° 3. 7: Granulocyte-Macrophage colony cultured in the presence of GM-CSF 10 
rig/mL and Epo 2 U/mL (May Grunewald Giemsa; x 100 magnification). 
Fig. N° 3. 8: Morphological details of a granulocytic colony cultured in the presence of 
GM-CSF lOrig/mL and Epo 2 U/mL (May Grunewald Giemsa; x 100 magnification). 
At present pre-activated tosyl beads with various monoclonal antibodies are 
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commercially available , making the selection procedures feasible for routine 
use. 
Although there was no marked difference in the cell yields between the two 
described methods, with panning a significantly higher population of cells 
retained trypan blue compared to the magnetic procedure, reflecting the high 
shear forces necessary to dislodge the attached cells from the antibody coated 
plastic surface leading to cell damage . 
Both selection techniques resulted in a marked enrichment for the clonogenic 
cells , approaching a the clonal efficiency of 5-10% for the total number of cells 
plated. Dose response results of the various combinations of cytokines were 
consistent with other reports (Ottman 1989), and indicated that maximal colony 
formation are reached with Epo between 2-10 U/mL, IL-3 10-50 TJg/mL, GM-
CSF 10-50 TJg/mL and SCF 40-100 TJg/mL. This data will prove helpful to 
study the behaviour of the selected progenitors in disorders where the interaction 
of progenitors and GF may be affected such as in myeloproliferation, 
myelodysplasia and plastic anaemia. 
In conclusion, this initial study confirmed that the selection of CD 34+ 
haematopoietic progenitors is feasible with both tested methods, leading to a 
marked enrichment in the colony formation. The magnetic separation was 
preferred as greater cell purities were obtained and selected cells had 
significantly better viability . 
CHAPTER4 
BONE MARROW STROMA AND STEM CELL 
FUNCTION IN UNTREATED PATIENTS AND 
PATIENTS WITH APLASTIC ANAEMIA 
RESPONDING TO ANTI-LYMPHOCYTE 
GLOBULIN. PILOT STUDY 
4. 1 INTRODUCTION 
Abnormalities in the bone marrow microenvironment (Hotta et al, 1985, 
Hintenberger et al, 1988) and of the haematopoietic stem cell (Marsh et al, 1990) 
have both been implicated as the probable mechanisms of bone marrow failure in 
aplastic anaemia. 
To further clarify the pathogenesis of this disorder, Marsh studied in cross culture 
experiments, non-adherent normal and aplastic marrow mononuclear cells. 
Progenitors were seeded on to pre-formed irradiated stroma from control or 
patients with non-acute aplastic anaemia, in the L TBMC assay (Marsh et al, 
1990). In this study, although the clonogenic output of normal cells was adequately 
supported by the microenvironment from the patients' stroma, target cells were not 
specifically selected for the early progenitor population. The possibility of normal 
non-adherent accessory cells contaminating the suspension thus reconstituting and 
correcting the aplastic L TMC, was not completely ruled out. 
To further define the mechanisms of the bone marrow failure and indicate the 
direction of future investigations, a pilot study was initiated to test the clonogenic 
potential of aplastic progenitors. These mononuclear cell fractions were compared 
with control precursors in cross-culture experiments on preformed bone marrow 
stroma employing a short-term stromal culture system (blastic colony assay, CFU-
bl, Gordon et al, 1987). In a further step, these control and aplastic CD 34+ 
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progenitors were quantified and cultured in the presence of recombinant growth factors in the mixed colony assay and their clonogenic potential compared. 
This initial study would also allow the writer to establish the technical problems associated with such methodology in patients with severe pancytopenia and intense marrow aplasia, specifically as seen during the acute presentation of the disease. 
4. 2 PATIENTS WITH APLASTIC ANAEMIA AND METHODS 
4. 2. 1 Description of the Patient Population 
In this pilot study, two patients with untreated aplastic anaemia, two in response after ALG therapy and another m early clinical relapse after this immunosuppressive therapy were studied and compared with five haematologically normal individuals. Their blood and bone marrow parameters are described in table N° 4. 1. 
TABLE 4.1 
STUDY POPULATION 
CLINICAL AND LABORATORY DATA 
TOTAL PATIENTS PERIPHERAL BONE NUMBER 
BLOOD MARROW CD34+ 
COUNTS CD34+ SELECTED NO STATUS Hb wee Plat PERCENT X 104 
g/dL x109/L xt09/L 
1 Response 10.22 2.9 104.0 0.5 3.3 
2 Response 9.7 3.1 97.0 0.3 2.2 
3 Relapse 7.4 1.8 49.0 0.0 0.5 
4 Untreated 8.8 0.6 19.0 0.0 <0.5 
5 Untreated 9.1 0.4 11.0 0.0 <0.5 
Peripheral blood values in patients with aplastic anaemia treated with ALG+ HDMP, or in those studied before receiving this therapy . 
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4. 2. 2 Bone Marrow Cells 
After informed consent had been obtained, bone marrow from patients with aplasia 
was aspirated under analgesia provided by intramuscular pethidine hydrochloride 
(1 mg/kg,) injected 30 minutes before the local anaesthetic. Control marrow was 
drawn under general anaesthesia from haematologically normal individuals during 
routine stemotomy for cardiovascular surgery and placed into tubes containing 
minimal essential medium (MEM, Gibco, Life Technologies, UK) and heparin 
(Pularin, 20 U/mL Nordisk, Johannesburg). Mononuclear light density cells 
collected from a polysucrose diatrizoate density gradient (1.077 g/mL, 
Hystopaque, Sigma, USA) were washed twice in aMEM and divided into two 
fractions, one for the formation of stromal layers and the second for the selection 
of the clonogenic progenitor cells. 
4. 2. 2. (a) Cultures of the Bone Marrow Stroma 
Stromal cultures were established from normal or aplastic subjects by suspending 5 
x I05/mL light density marrow cells in aMEM containing 12.5% each of horse 
serum and fetal calf serum, supplemented by 2 x 1 o-6 hydrocortisone. One milliliter 
of the suspension was cultured in 33 mm petri dishes (Falcon) at 37° C in 5% CO2 
in high humidity. The medium was changed weekly and upon confluence, the 
cultures were irradiated at 0, 75 Gy/min to a total of 15 Gy. At regular intervals 
adherent layers were inspected under phase contrast microscopy and analyzed 
morphologically for gross anomalies in the development of the stroma. 
4. 2. 2. (b) Blastic Colony Assay (CFU-bl) 
The second fraction was suspended in aMEM containing 2% FCS and monocyte 
depleted by two-hour incubation in 15 x 220 mm plastic dishes (Bibby, UK). 
Aliquots were taken for cytochemical and immunophenotypic determinations, and 
5 x 1 os selected cells were layered over the preformed normal and aplastic stromal 
cultures for two hours at 3 7° C, for adhesion to take place. The stroma non-
adherent population was decanted by standardized washing with tissue culture 
medium. Adhesive precursors were covered with O. 3 % agar and cultured for five 
days at 37° C in 5% CO2 and 90% humidity. Blastic colonies (CFU-bl) (Gordon et 
al, 1987) were scored as aggregates containing more than twenty cells. 
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4. 2. 2. (c) Immunomagnetic Selection of the Haematopoietic Progenitor Cells 
The remainder of the monocyte-poor marrow was lymphocyte-depleted by 
incubating cells with CAMPATH 1 M (6.25 mg/mL; 0.01 mL/106 cells) (Hale et 
al, 1983) for 50 minutes at 37° C in the presence of 10% human AB serum as a 
source of complement 0N estem Province Blood Transfusion Services; Cape 
Town, South Africa). Accessory cell-free fraction was re-suspended in 0.2 rnL 
PBS (pH 7.4) and incubated with anti-CD 34 (MY 10 Becton-Dickinson) at 4° C 
for 30 minutes in continuous rotation. Excess antibody was washed off, and 
labelled cells exposed to 5-15 x 106 paramagnetic particles coated with high 
affinity goat anti-mouse immunoglobulin (Magnetics Institute, Boston Mass) . A 
positive selection was achieved with a magnetic field applied to the side of the 
tube. As described in the previous chapter, aliquots of the initial light density and 
selected populations were taken for morphological, cytochemical, 
immunophenotypic characterizations and cell viability studies. 
4. 2. 2. (d) Clonogenic Tests. Mixed Colony Assay 
Selected cells were re-suspended in IMDM, and 1-10 x 103 cells cultured for 
fourteen days in the mixed colony assay in IMDM (with L-Glutamine, Gibco) in 
the presence of 2 U erythropoietin and rh-IL 3 10 11g/mL or rh GM-CSF 10 
11g/rnL; supplemented by 5 xl0-5 mercaptoethanol and 30% FCS in 0.3% agar. All 
results were corrected and expressed as colonies / 1 os cells. Erythropoietin was 
generously donated by Bioclones (Sandton, Transvaal). Once reconstituted, it was 
kept at 4° Cat a concentration of 1000 U/mL. IL-3 and GM-CSF were gifts from 
Amgen (Amgen Thousand Oaks, California) with specific activities of 107 and 108 
U/mg respectively. 
4. 3 RESULTS 
4. 3. 1 Cultures of the Bone Marrow Stroma 
Both normal and aplastic stroma became confluent between three and four weeks 
from initiation. On inspection, there was no morphological difference between 
normal and chronic aplastic stromal cultures, while a reduction in the macrophage 
numbers was evident in the cultures derived from untreated patients. 
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4. 3. 2 Blastic Colony Assay (Fig. N° 4. 1) 
Both normal and aplastic stromal layers supported the formation of CFU-bl to an 
equal extent. There was, however, a marked reduction in the number and size of 
colonies generated from the marrow of patients with treated aplasia when grown 
over normal stroma. These aggregates were often poorly circumscribed. No 
clonogenic growth occurred from progenitors derived from patients with untreated 
aplasia. 
4. 3. 3 Immunomagnetic Progenitor Cell Selection and Mixed Colony Assay 
In patients with aplastic anaemia following immunosuppressive treatment, the CD 
34 positive population in the bone marrow was quantitatively decreased to 0.1 and 
0.2% of mononuclear cells. Absolute numbers of the selected populations were 
also markedly reduced in the treated group (mean 2.0 x 104, range 0.5-3 .3) while 
in those with the untreated disease, this population was practically undetectable 
(fewer than 0.5 x 104 /mL cells). 
Furthermore, cultures of accessory-free population defined as containing fewer 
than 5% of CD 3 and CD 14 positive cells, unreactive with a-naphtyl butyrate 
esterase and positively selected to a purity of greater than 80%, showed a marked 
reduction in the colony growth when compared with normal precursors in response 
to IL3 and GM-CSF (Table 4. 2 and Fig N° 4. 2, page 69). Here again, no growth 
was elicited from cells derived from patients with untreated aplasia. 
4. 4 DISCUSSION OF THE RESULTS 
The blastic colony assay (CFU-bl) exploits the natural adhesive properties of early 
bone marrow progenitors to allogeneic myeloid stroma, supporting the 
development of colonies of undifferentiated blasts. These precursors have been 
shown to form secondary colonies, and have cell kinetics similar to fetal cord blood 
derived progenitors (Gordon et al, 1985, 1987). 
Morphological inspection of the diseased stroma failed to reveal any obvious 
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differences with the control cultures. The only feature observed was fewer 
macrophages in the stroma derived from the untreated patients. Functionally, 
however, no differences in the CFU-bl numbers were elicited compared with 
control layers, seeded with normal light density cells. These data suggest that the 
aplastic stroma has no significant inhibitory action on the normal cells studied. 
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Fig. N° 4. 1: Stromal blast cell colony assay. N = Marrow obtained form 
normal volunteers. UA = Marrow from patients with untreated aplastic 
anaemia. T AA = Marrow from patients who have previously received 
antilymphocyte globulin. 
Compared to control cultures, the number ofblastic colonies in patients responding 
to immunosuppressive therapy, was markedly decreased and absent in those 
studied during the acute phase of the disease. This is consistent with the 
immunofluorescence studies that showed a striking reduction in the CD 34 positive 
progenitors from aplastic marrows. This observation would suggest that with the 
current methodology, extensive studies on the bone marrow cells of patients with 
untreated severe aplasia would be unsuccessful. 
As expected, when positively selected progenitors were cultured in the mixed 
colony assay in the presence of recombinant growth factors, despite equal numbers 










TABLE 4. 2 
SELECTED POPULATIONS 
COLONIES x 105 
IL3 50 T]g/mL GM-CSF 50 T]g/mL 
BFU-e CFU-e CFU-gm BFU-e CFU-e CFU-gm 
110 107 21 60 290 100 
210 220 98 110 120 150 
67 100 52 49 73 58 
0 3 0 0 9 0 
0 I 0 0 2 0 
482 2032 231 380 928 372 
Results of the clonogenic growth of CD 34+ progenitors in the mixed colony 
assay from patients with treated (N ° 1, 2 and 3), untreated aplastic anaemia (4 and 
























Fig. 4. 2: GEMM: CFU assay results. CD 34+ cells from normals (N) 
compared with those derived from patients with treated aplastic 
anaemia (T AA) cultured in the presence of rh Epo with IL-3 or GM-
CSF. 
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However, in those recovering after immunosuppression, the clonogenic output was 
detectable but appeared markedly reduced. This result is consistent with the 
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postulate that the haematopoietic abnormalities reside mainly within the HSC. The 
possible alternatives include, firstly, that stem cells that survive the initial attack 
(such as immunological or irradiation) and repopulate the bone marrow are 
inherently hypoproliferative and the normal balance between positive and negative 
regulators favours sub-optimal colony formation (Young, 1992). Alternatively, 
continuing immunological suppression by the microenvironment (Merchav, 1988, 
Hotta et al, 1986, Bacigalupo et al, 1984, Zoumbos et al, 1985, Hintenberger et 
al, 1988) or a deranged interaction between growth factor receptors and ligands 
within the bone marrow milieu leads to a reduction in the clonogenic output. 
In the current pilot study it is concluded that aplastic stroma is not suppressive to 
the development of normal progenitors. This implies that the primary defect 
probably resides with the aplastic stem cell population. To confirm this hypothesis 
a more extended study was initiated, where a purified population of progenitors 
positively selected for the CD 34 membrane antigen and devoid of accessory cells 
was cultured on preformed stroma or subjected to incremental concentrations of 
various growth factor combinations. 
Finally, although irradiation with 15 Gy does not affect normal or aplastic stroma, 
it remains possible that this leads to damage of the of resident radiosensitive 
alloreactive accessory cells, allowing normal proliferation of the control 
progenitors. Evidence also exists that following this physical insult, release of GFs 
from stromal cells is detected (Tsuboi et al, 1991), altering further the 
interpretation of the results. To avoid these technical variations, future studies 
would employ unmanipilated stromal layers as negative controls. 
CHAPTERS 
IN APLASTIC ANAEMIA THE BONE MARROW STROMA 
DOES NOT INHIBIT NORMAL CLONOGENIC GROWTH 
5. 1 INTRODUCTION 
Under steady state conditions, commitment, differentiation and maturation of the 
haematopoietic stem cell occur in the bone marrow. Although the activation of 
programs for cell division appears to be of a stochastic nature (Suda et al, 1983), it 
is generally accepted that the amplification of the various cell lines and signalling 
towards maturation are controlled by stromal cells, extracellular matrices and 
growth factors present in this organization that are named collectively as the bone 
marrow microenvironment (Gualtieri et al, 1987). Elements in the stroma appear 
to provide both structural adherence sites and to secrete positive and negative 
growth-regulating molecules that allow early self-replicating progenitors to sustain 
a stable haematopoiesis (Gordon et al, 1987). 
In aplastic anaemia, the nature of the haematopoietic defect remains unknown but 
as reviewed in Chapter 1 abnormalities in the myeloid microenvironment (Hotta et 
al, 1985, Hintenberger et al, 1988, Juneja et al, 1984) or in the stem cell pool 
(Aoki et al, 1990) have been documented. In addition, well defined animal models 
exist of genetically anaemic mice where the stroma (S/Sl) or the haematopoietic 
stem cells (WMN) are defective (McCulloch et al, 1965; Bernstein et al, 1968). 
Since an integral part of the bone marrow microenvironment are cells of the 
immune system (McGuiness et al, 1991, Shibata et al, 1986) and of monocyte 
origin (Strobel et al, 1986) that are known to secrete growth modulating 
molecules, alterations in the immunity may indeed affect haematopoiesis. 
Furthermore, as described in Chapter 2, immunomodulation with anti-lymphocyte 
globulin or cyclosporine have led to successful reversal of this syndrome in the 
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majority. Nevertheless, some patients who respond to these therapies, on more 
detailed inspection have derangement in their haematopoiesis. Here, in addition, 
the function of the differentiated progeny appears abnormal and of more concern is 
that, in a subgroup, evolution to myelodysplasia, PNH and acute leukaemia has 
been described (Tichelli et al, 1988 [a and b]) . 
To define the relevance of each pathogenetic mechanism, Marsh studied patients 
with aplasia after immunosuppressive therapy, with the LTBMC system. In cross-
over experiments, marrow cultures of adherent-cell-free light density cells were 
seeded onto irradiated preformed stroma. She concluded that, in all patients tested, 
a primary stem cell defect was present. Of importance was that, regardless of the 
degree of response or treatments received, significant reductions in the CFU-GM 
output were found . In addition, in one patient a combined stromal defect was also 
demonstrated (Marsh et al, 1990). 
In this work, however, "engraftment" with normal elements present in the 
unselected plastic non-adherent population correcting a latent abnormality was not 
excluded. This point was partly addressed in a limited follow-up study when 
purified populations of aplastic or control CD 34+ cells were cultured over 
preformed stromal layers (SL). Results of this work confirmed the initial findings 
(Marsh et al, 1991). 
In a modification of this system that exploits the adhesive properties of clonogenic 
cells, it is possible to examine an early population of undifferentiated blasts, (CFU-
bl) (Dowding et al, 1992, Gordon et al, 1987). These resemble murine spleen 
colony-forming cells in their resistance to cycle specific cytotoxics (Gordon et al, 
1985). They are able to produce secondary blastic colonies with a repopulating 
potential similar to, or exceeding that of umbilical cord blasts (Gordon et al, 1987). 
Applying this model, the writer has previously reported that both the stroma 
derived from untreated aplastic patients or from those responding to 
immunosuppression support growth of normal precursors effectively. However, 
aplastic haematopoietic progenitors were defective (Novitzky et al, 1991). We 
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have now extended these studies and confirm that the marrow stroma in aplasia 
allows the development of normal blastic colonies adequately, while the clonogenic 
growth of stroma adherent and non-adherent CD34 positive progenitors is 
significantly reduced. 
5. 2 Study Population (Table 5. 1) 
Sixteen patients and seven control subjects gave written consent according to 
Institutional guidelines to donate bone marrow for the clonogenic studies. 
5. 2. 1 Patients with Aplastic Anaemia 
Between February 1984 and March 1991 , thirty-five patients with severe acute 
aplastic anaemia were referred to our Institution for further evaluations. One 
subject had a rapid improvement following a therapeutic abortion, while the rest 
received a uniform protocol of anti-lymphocyte globulin and high-dose methyl-
prednisolone, followed by oxymetholone for six to nine months (Novitzky et al, 
1991 , Chapter 2). Twenty-three fulfilled the criteria for response (freedom from 
transfusions, granulocyte count of > 1 x 1 o9, and platelets of >40 x I09) and at a 
median of 1320 days, 66% are alive. 
Their median time in response was four years (1-8) . Three required further 
immunosuppression, and two are currently receiving cyclosporine and androgenic 
corticosteroid maintenance. Two patients developed haemolysis, haemoglobinuria 
and a positive Ham's test with clinical features of paroxysmal nocturnal 
haemoglobinuria (PNH). The median age is 33 (17-61), nine are females and for 
the whole group the median performance status is O (WHO). 
5. 2. 2 Control Population 
Progenitor cells in the control population derived from haematologically normal 
individuals undergoing sternotomy for cardiac surgery under general anaesthesia. 
5. 3 METHODOLOGY FOR THE CULTURE OF THE BONE MARROW 
STROMA AND THE BLASTIC COLONY ASSAY 
5. 3. 1 Bone Marrow Cells 
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In the study population, bone marrow was aspirated under pethidine HCl (1 mg/kg 
IM) sedation and local anaesthesia. Both normal and aplastic marrow-rich blood 
was placed into tubes containing preservative-free heparin (Pluralin, 10 U/mL; 
Nordisk, Johannesburg), and a monocellular suspension was achieved by forcing 
marrow cells through 23 gauge needles diluted 1/5 in Minimal Essential Medium 
(aMEM) (Gibco, Life Technologies, UK) and layered to on a polysucrose 
diatrizoate density gradient (1.077 g/mL, Hystopaque, Sigma, USA). 
Light density cells obtained from the interface were washed three times in the same 
medium and re-suspended in 10 mL. Aliquots were taken for morphological 
assessment, indirect immunofluorescence and quantitative determinations with an 
electronic particle counter (Multisizer, Coulter Electronics, USA). Cell suspension 
was then divided into two fractions, one to establish the adherent stroma and the 
other for the selection of the progenitor cells. 
5. 3. 2.- Cultures of the Bone Marrow Stroma 
Throughout the study sequential stromal cultures from three haematologically 
normal males aged 34, 41 and 42, who had undergone surgery for coronary artery 
by-pass grafting were employed. In morphological and functional studies their 
stroma was compared with aplastic SL. Neither the patients nor the controls had a 
history of recent inflammatory or infectious disorders. 
Normal or aplastic light density bone marrow cells were suspended in aMEM 
containing 12% of horse serum (HS; GIBCO; Life Technologies, UK) and foetal 
calf serum (FCS; GIBCO), supplemented with hydrocortisone 2 x 1 o-6 and 
gentamycin 5 mg/mL. Mononuclear cells were cultured in 33 mm Petri dishes (T. 
C. Dishes; Bibby-2500 B, UK) at a cell concentration of 0.5 x 106 per dish at 37°C 
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m 90% humidity and gassed with 5% carbon dioxide until stroma became 
confluent. The medium was changed weekly throughout the culture life. 
5. 3. 3 Selection of the Haematopoietic Progenitor Cells 
The methodology for CD 34+ cell selection has been detailed in chapter three. 
Briefly, lymphocyte and monocyte-poor progenitor cell concentrates were re-
suspended in 0.2 mL of cold (4° C) phosphate buffered saline (PBS) containing 
0.02 mL/107 cells of anti human CD 34 antigen murine monoclonal antibody and 
incubated at 4° C for 30 minutes. Labelled cells were then washed three times in 
PBS containing 2% AB serum and exposed at 4° C to polystyrene coated 
paramagnetic beads at a cell concentration of 5-10 x 109/L, for 30 minutes in 
continuous rotation. Incubation with the paramagnetic particles and magnetic 
separation were performed twice on labeled cells. 
To free cells from beads, selected cells were re-suspended in O. 1 mL of PBS 
containing 0.01 mL of a polyclonal murine immunoglobulin (Detachabead, Dynal) 
at room temperature for 60 minutes in a continuous rocking motion and exposed 
to the magnetic forces again. Cells freed from beads were recovered, aliquots taken 
for immunofluorescence studies ( as described in chapter three) and viability 
determined by trypan blue exclusion. Recovered cells were counted in a 
haematocytometer and numbers adjusted to a concentration of 1-5 x 104/ mL. 
5. 3. 4 Blastic Colony Assay 
Magnetically selected 1 x 1 o4 CD34 positive cells obtained of the control 
population or patients with aplasia were layered in duplicates in cross-culture 
experiments on either preformed normal or aplastic SL for two hours, to ensure 
optimal adherence. The unattached cells were then removed by standardised 
washing with aMEM. Progenitors affixed to SL were covered with 1 mL of O. 3 % 
agar (final concentration) in aMEM containing 30% FCS, and cultured for 5 days 
at 37° C in 5% CO2 (Gordon et al, 1987). 
Aggregates defined as containing more than twenty cells were scored with an 
inverted microscope on days five and seven of culture. Layers that had not been 
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seeded with CD 34+ cells served as negative controls. CD 34 positive cells from 
six normal subjects were also co-cultured on normal stroma. CFU-bl numbers were 
then determined to provide comparative values to contrast for colony numbers 
obtained from control progenitors layered on aplastic stroma. 
Following the two-hour incubation, non-adherent CD 34 positive progenitors were 
washed off SL, pooled and cultured in Iscove's modified Dulbecco's medium 
(IMDM, with L-Glutamine, Gibco) containing 30% FCS and 15% PHA 
lymphocyte conditioned medium in agar 0.3% (final concentration) in cluster 
dishes (Nunclon, Delta, Code 176740; UK) for 14 days at 37° C in a COrrich, 
humidified atmosphere. As morphological and cytochemical determinations of 
cytospin specimens from progenitors eluted from two-hour incubation on stroma 
showed significant contamination with stromal macrophages ( absent on the CD 
34+ pre-incubation specimens), aggregates of these cells were not scored. Only 
colonies of granulocytes and granulocyte-macrophage CFU containing more than 
40 cells were counted and results of colony numbers from these duplicates were 
divided by 2 and expressed /1 o4 cells. 
5. 3. 5 Morphological and Cytochemical Assessment 
To define the stromal elements, upon confluence, representative cultures were 
dried and stained in situ with May-Grunewald-Giemsa (Lewis et al, 1986), or 
incubated with 1 mL O .1 % bovine trypsin (Difeo Corp, Detroit, MI) for 10 minutes 
at 37° C. This enzyme was then inactivated with cold FCS and washed twice in 
aMEM. Cytospins of the complete stromal suspension were prepared (Shandon) 
and stained with May Grunewald Giemsa, Sudan Black, Oil Red 0 , and alkaline or 
acid phosphatases. In this analysis of the cytochemistry of the marrow stroma, 
differential counts were performed, and results compared between patients and 
controls. 
5. 3. 6 Statistical Analysis 
Standard two-way analysis of variance was used to determine the significance of 
differences between groups of cultures, or a single culture versus control group. 
Student's t test was used to assess the standard error of the difference between two 
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means in the results of colony assay data. 
5. 4 THE BONE MARROW STROMA IN APLASTIC ANAEMIA. 
RESULTS OF THE BLASTIC COLONY ASSAY 
5. 4. 1 Morphology and Cytochemical Staining of the Stroma (Table 5. 1) 
Both normal and aplastic stroma became confluent at a median of four weeks (3-4 
Vs 3-5). In one patient it did not reach confluence by five weeks, when it 
commenced to lift off in the majority of the dishes. 
When inspected under phase contrast microscopy, no obvious abnormalities were 
detected in the stroma from patients with marrow aplasia. Morphologically, they 
looked similar to normal stroma (Fig. N° 5. 1 and 5. 2, page 79 and 80). Similarly, 
there was no difference in the stromal architecture shown by the various stains 
used in situ. Differential counts of stained cytospin preparations from normal 
controls showed that Sudan black positivity was present in a median of 13% (SD 
7.2) of cells, oil red O in 9% (SD 4.1) acid phosphatase 72% (SD 17.5) while 
alkaline phosphatase was positive in 61 % (SD 17.2). 
In stroma from patients with aplasia, the respective values were: Sudan black 16% 
(SD 7.7), oil red O 3% (SD 2.5%), alkaline phosphatase 56% (SD 11.5) and acid 
phosphatase 64% (SD 20). Between the two groups, none of these values differed 
significantly (Table N° 5. 1, page 78). 
5. 4. 2 Selection of the Haematopoietic Progenitor Cells (Table N° 5. 2) 
Immunofluorescence studies on unselected light density cells from patients with 
aplasia resulted in a median of 0.65% CD 34+ (SD 0.35) cells. These were 
significantly fewer progenitors than normal controls at 1.6% (SD 1.38) (p < 0.05). 
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TABLE 5.1 
CYTOCHEMICAL DEFINITION OF THE BONE MARROW STROMAL 
LAYERS 
ALKALINE ACID 
STROMA SUDAN BLACK OREDOIL PHOSPHATASE PHOSPHATASE 
MEAN SD MEAN SD MEAN SD MEAN SD 
APLASTIC 16.00 7.76 3.06 2.52 55.56 11.43 64.31 19.95 
NORMAL 13.00 7.20 9.00 4.10 61.00 17.20 72.00 17.50 
Cytospins of suspensions of bone marrow stroma from normal controls and patients with 
aplastic anaemia were stained with cytochemical stains and mean % (SD) positivity 
determined on 300 cells. 
When corrected to an initial cell number of 100 x 106 light density cells, the total 
median number of selected progenitors harvested was higher within the control 
population at 0.539 x 106 vs 0.116 x 106 from the study group (p= 0.18). 
Upon morphological or immunophenotypic examination of the selected fraction, 
there was no obvious difference in the cell content (Table N° 5. 2, page 82). 
Morphologically, undifferentiated blasts represented a median of 80 and 82.5% in 
each group. The majority of contaminating cells were of the early granulocytic 
series, while monocytic cells were always < 2% in both selected groups. 
5. 4. 3 Blastic Colony Assay (Table N° 5. 3) 
Normal progenitor cells selected for the CD 34 antigen and cultured for five days 
on aplastic stroma gave a mean of 103 .1 colonies/104 cells (Median 104; SD 30.4). 
Two types of colonies were obvious: the majority belonged to colonies that were 
adherent and well circumscribed, compact, round or more often elongated, 
following the body of fibroblastic cells in the stroma (Fig N° 5. 3 to 5. 5, pages 81 
and 84), while the second group appeared to detach from the stroma and rise into 
to the agar . 
The mean number of 6 normal CFU-bl on control stroma was 117 colonies/I 04 
cells (mean 109, SD 20.4) (p > 0.05) on day five, and this number did not change 
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significantly on day seven, when some clones became looser and started detaching 
from the adherent layer. None of the SL that were not seeded with selected 
progenitors showed any CFU-bl formation . 
Fig. N° 5. 1.- Normal confluent bone marrow stroma as observed with contrast microscopy (x 100 
magnification). Fat cells are prominent and surrounded by fibroblasts . 
When aplastic CD 34+ precursors were incubated on normal stromal cultures, a 
mean of 41.06 colonies /104 cells (median 29, SE 42.9) was scored (Fig N° 5. 7, 
page 86). This was significantly lower than colony numbers obtained from normal 
CFU-bl on aplastic SL (p= 0.0002 exact one tailed T test) . The majority of the 
colonies were small, loose, with many scattered cells (Fig. N° 5. 6, page 85). When 
observed on day seven, although the colony number scored did not change 
significantly, some aggregates continued to increase in size even until day ten, 
when all cultures were terminated. 
5. 4. 4 Stroma Non-Adherent Clonogenic Growth (Table 5.3) 
When cultures from stroma non-adherent cells decanted after a two-hour incubation 
and grown for fourteen days in the presence of PHA-LCM were scored for 
clonogenic growth, results revealed that both normal and aplastic CD 34+ had 
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Fig. N° 5. 2.-Confluent bone marrow stroma from a patient with aplastic anaemia in partial 
remission. Contrast microscopy (x 100 magnification). 
proportionately similar numbers of stroma adherent and non-adherent precursors. 
Specifically, when aplastic CD 34+ were incubated on normal stroma, the mean 
CFU-bl/CFU-gm ratio was 41.06 (SD 42.9) : 142 (SD 104.8). Corresponding 
results from normal CD 34+ on aplastic stroma were 103.1 (SD 30.4): 361.7 (SD 
91.3) and similar to control progenitors off normal adherent layers at 117 (SD 
20.4): 335 (SD 56.8) (Fig. N° 5. 7, page 86). 
Furthermore, when results of adherent and non-adherent aplastic colonies were 
combined as a total clonogenic potential and compared with the normal composite, 
diseased CD 34 positive cells had significantly lower colony output ( combined 
mean 185.8 vs 447.1 ; p= 0.0009, exact two-tailed). These data indicate that both 
stroma adherent and non-adherent progenitors are decreased in aplastic anaemia, 
and alterations in the adhesion to the stroma were not a significant cause of the 
reduction in the CFU-bl in this disease. Alternatively, these results may argue for a 
relative increase in the CD 34+ non-clonogenic population within the aplastic 
fractions. Nevertheless, because CFU-bl were generally smaller in size and took 
longer to develop, an intrinsically hypoproliferative population is favoured . 
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5. 5 DISCUSSION OF THE RESULTS 
Haematopoiesis in mammals is under the control of a variety of positive and 
negative regulators with feed-back mechanisms (Layton, 1989) between the mature 
elements, the progenitor cell pool and the bone marrow microenvironment 
(Gordon, 1987). 
Fig. N° 5. 3: Blastic Colony Assay. Contrast Microscopy of a day 5 colony of haematopoietic 
progenitors derived from normal CD 34+ adherent cells (x 100 magnification). 
It is likely that steady-state haematopoiesis is maintained by the bone marrow 
stroma, either through direct cell membrane interactions as suggested by co-
cultures with formalin fixed NIH-3 T3 fibroblasts (Roberts et al, 1987), or through 
the release of growth factors (Gordon et al, 1987 Kittler et al, 1992). These 
cytokines are secreted by the stroma, or resident cells of the immune system 
(lymphocytes, macrophages), which then act on receptors present on the target 
progenitor cell membranes (Nicola and Metcalf, 1984, 1985). 
However, in vitro lymphocytes and monocytes can also down regulate myeloid 
proliferation (Irvine et al, 1991), independently from Interferon and IL-I secretion. 
Alternatively, they can also induce TNF production by accessory cells. 
TABLE 5. 2 
PROGENITOR CELL SELECTION 
CELL POPULATION 




































































Characteristics of the light density cell population of the patient and control groups. 
Results of purification procedures and positive selection for the CD 34+ cells for both 
populations are presented. ** Denotes statistical significance (p < 0.05). 
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All these effects may lead to inhibition of both erythropoiesis (Johnson et al, 1991) 
and myelopoiesis (Kobari et al, 1990, Klimpel et al, 1982), which can be reversed 
by increments of colony stimulating factors in the cultures (Klimpel et al, 1982). 
Therefore if the net secretion of inhibitory molecules predominates, it will result in 
a limited marrow output (Raefsky et al, 1985). 
In aplastic anaemia an overall activation of the immune system has been described 
with increase production of IFN-g (Zoumbos et al, 1985), neopterin and TNF 
(Hintenberger et al, 1988), from enhanced spontaneous secretion of these 
cytokines and increased bone marrow suppressor cell activity from CD 8+ Fe 
Gamma+ lymphocytes (Bacigalupo et al, 1984). 
TABLE 5. 3 
STROMA ADHERENT AND NON-ADHERENT COLONIES 
NORMAL STROMA APLASTIC NON- APLASTIC STROMA NORMAL NON-
PATIE T APLASTIC CD 34+ ADHERENT CD 34+ CONTROL CD 34+ ADHERENT CD 34+ 
CFU-bl CFU-mt CFU-bl CFU-mt 
1 15.0 99.0 82.0 214.0 
2 12.0 30.5 92.0 -
3 6.0 129.0 72.0 502.5 
4 27.0 306.0 - -
5 82.0 367.0 102.0 310.0 
6 20.0 38.0 104.0 384.0 
7 181.0 316.0 111.0 210.0 
8 49.0 64.0 143 .0 369.0 
9 20.0 80.0 105.0 -
10 32.0 147.0 71.0 -
11 2.0 63 .0 98.0 -
12 63 .0 165.0 186.0 390.0 
13 38.0 141.0 108.0 471.0 
14 26.0 103 .0 108.0 376.0 
15 50.0 - 104.0 410.0 
16 34.0 91.0 61.0 344.0 
Absolute values of stroma adherent/non-adherent progenitors from patients with non-acute 
aplastic anaemia cultured on normal stroma and of progenitors from normal subjects on 
aplastic stroma. 
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A few studies have suggested that the mechanisms of the pancytopenia originate 
from abnormalities in the marrow microenvironment (Knospe et al, 1971 , Ershler, 
et al, 1980, Hotta et al, 1985). Specifically, marrow inhibitory effects and 
alterations in certain cell populations have been demonstrated both in the acute 
presentation and following immunosuppressive therapy (Anderseen et al, 1989 
Hinterberger et al, 1988, Bacigalupo et al, 1984). However, when tested, aplastic 
stromal cells secreted adequate amounts of G-CSF, GM-CSF and IL-6, 
constitutively or after induction with IL-1 (Kojima et al, 1992). This behaviour is 
consistent with two recent studies that suggested that defects at this level are rare 
in aplasia (Marsh et al, 1990, 1991). 
The initial pilot study demonstrated that the stroma in both acute and non-acute 
marrow aplasia supports normal CFU-bl adequately (Novitzky & Jacobs, 1991, 
Chapter 4). To examine further the interactions between the bone marrow 
progenitors and the adherent layers, in the current study we employed selected CD 
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Fig. N° 5. 4.: Blastic colony assay. Photomicrograph of a day 5 stromal colony derived from 
normal CD 34+ progenitors (May Grunewald Giemsa; x 200 magnification). 
Fig. N° 5. 5: Blastic colony assay. Details of a day 5 colony. Note the conspicuous 
nucleoli with lack of cell differentiation (May Grunewald Giemsa; x 600 magnification). 
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Fig. N° 5. 6: Contrast microscopy of a day 7 stromal colony derived from aplastic CD 34+ 
progenitors. 
34+ progenitors and chose the short blast-colony assay (Gordon et al, 1987) for 
various reasons. Firstly, it provided clear end-points in the form of quantifiable 
CFU-bl. Secondly, the adhesive interactions of the CD 34+ population with the 
stroma could also be tested, analyzing in clonogenic assays the selected stroma 
non-adhesive population and determining their proportions. However, in this study 
the percentage of non-haematopoietic cells such as endothelial, fibroblastic cells or 
B lymphocytes in the CD 34+ selected populations were not determined (Simmons 
et al, 1989). These non-myeloid cells from normal suspensions did not appear to 
affect the behaviour of the aplastic stroma as demonstrated by similar growth of 
control CFU-bl on normal or aplastic SL. This analysis was unable to exclude 
completely the possibility that such populations present in the aplastic suspension 
could have had inhibitory effects on their own myeloid precursors. Nevertheless, 
this was thought improbable due to the low cell numbers remaining adherent to the 
stroma. 
CLONOGENIC GROWTH 
STROMA ADHERENT vs NON-ADHERENT 
CD 34+ PROGENITORS 
A/N CFU bl/gm 
Colonies/10.000 CD 34+ cells 
NIA CFU bl/gm NIN CFU bl/gm 
I** p < o.os I A: aplastic anaemia N: control 
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Fig. N° 5. 7: Clonogenic output of CD 34 + cells from controls and patients with aplasia on the 
CFU-bl and CFU-gm assays. Aplastic CD 34 + cells were incubated on control stroma (NN) and 
compared with normal selected precursors cultured on aplastic stroma (NIA) or control stroma 
(NIN) 
The original method was modified in that the irradiation of the allogeneic stroma 
was omitted, on the one hand to avoid damage to the possible presence of 
radiosensitive cells of the immune system that in vivo modulate the aplastic 
haematopoiesis, and on the other to avert the release of bursts of growth factors 
that follows this physical insult (Gualtieri et al, 1984, 1987, Tsuboi et al, 1991 ). 
Upon confluence, in situ morphological inspection of the cultures failed to 
demonstrate significant differences between normal and diseased stroma. 
Cytochemistry of the trypsinised and fixed stromal layers also showed similarity in 
the cell populations staining for Sudan black (macrophages), ring red O (fat cells), 
and those reacting with acid or alkaline phosphatases (fibroblasts, reticular cells). 
In this study it is confirmed that the bone marrow stroma in aplasia supports 
normal CFU-bl adequately with a clonogenic output that is no different from that 
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of control layers (Table N° 5.3 , page 81). The data would suggest that, as tested 
with this assay, levels of negative regulators in aplastic stroma are not significantly 
higher than that of control layers and support the conclusion that defects at this 
level are rare (Marsh et al, 1990). It may still be possible that aplastic stroma is 
unable to sustain earlier progenitors that are not tested by this system. This is 
unlikely since no such abnormalities were detected in similar patients with the Long 
Term Bone Marrow Culture assay, where a wider range of haematopoietic 
progenitors are examined (Marsh et al, 1990). 
Of greater relevance is that in this disease, selected CD34+ precursors formed 
significantly fewer colonies on normal stroma, and generally these showed a sub-
optimal development. In addition, some required longer to develop, suggesting that 
clonogenic potential had not been realized even after five days as is characteristic 
of the normal group. Furthermore, when stroma non-adherent CD 34+ cells w--ere 
cultured in semi-solid systems supplemented with PHA-LCM, CFU-gm colony 
numbers were proportionately similar but significantly lower in the diseased group 
than the control (Fig N° 5. 7, page 86). These observations for the first time 
provide evidence that the fraction of dividing cells among the adherent and non-
adherent populations is markedly reduced in this disease, and that decreased CFU-
bl were not related to alterations in the adhesiveness to stroma. 
These results are consistent with the hypothesis that the haematopoietic 
abnormality in these patients lies within the progenitor cell population. Whether the 
defective cells have been selected during the initial marrow damage or resulted 
because of ongoing immunological action remains to be clarified. 
CHAPTER6 
THE BONE MARROW PROGENITOR CELLS IN 
APLASTIC ANAEMIA HA VE A SUB-OPTIMAL RESPONSE 
TO GROWTH FACTORS 
6. 1 INTRODUCTION 
Little is known about the various mechanisms that lead to bone marrow failure in 
aplastic anaemia. In this regard, while strong evidence accumulates suggesting 
primary stem cell abnormalities, the inhibitory roles of the immune system and the 
marrow microenvironment still remain controversial (Young 1992, Fujiwara et al, 
1990). 
In the previous chapter it has been shown that the bone marrow stroma in non-
acute aplasia supports adequately normal CFU-bl. This is a sub-population of 
clonable progenitors with a very immature phenotype (Gordon et al, 1987 [a]), 
indicating that the level of negative regulating peptides in the stroma is not 
excessive. Similar conclusions were reached by other studies, employing in cross-
culture experiments the L TBMC system, even when stroma had been seeded with 
CD 34 positive selected progenitors (Marsh et al, 1990, 1991). However, none of 
them provided further evidence regarding the possible mechanisms for the bone 
marrow dysfunction. 
As reviewed in Chapter 1, steady state haematopoiesis is the result of interactions 
of positive and negative regulators secreted locally by the stroma (Sieff et al, 1987, 
Cannistra et al, 1988, Zipori et al, 1989, Gualtieri et al, 1984, 1987), acting 
through specific receptors on target cell membranes (Bude! et al, 1990, D'Andrea 
et al, 1990). Additionally, autocrine modulation of the haematopoietic progeny has 
been described (Gasson et al, 1987; Rambaldi et al, 1987; Young & Griffin, 1986) 
constitutively or in response to indirect signals (Sieff, 1987), as occurs with the 
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release of M-CSF or G-CSF following the exposure of monocytes to IFN-g, IL 1 
or endotoxin (Cannistra et al, 1988). Various purification steps and positive 
selection for haematopoietic progenitor cells markedly decrease these interacting 
signals from accessory cells, allowing an easier interpretation of the behavior of the 
populations under scrutiny. 
Clinical experience indicates that some patients with aplastic anaemia respond to 
therapy with pharmacological doses of Epo, (Bessho et al, 1990) GM-CSF 
(Vadhan-Raj et al, 1988) or G-CSF (Kojima et al, 1991). This response suggests 
that despite intense pancytopenia, under appropriate stimulation, amplification of 
the terminal elements was still possible and resulted in improvements in blood 
counts of clinical significance. These were transient however, and only directed at 
the cell lineage under stimulation. Similar responses were observed in vitro after 
marrow mononuclear cells were exposed to erythropoietin, at concentrations that 
in normal cultures were well above plateau growth (Aoki et al, 1990). However, it 
remains unclear why clinical responses are not sustained. 
Unresponsiveness to a specific cytokine can result from lack of target cells or be 
the consequence of abnormal receptor-ligand interactions. However, resistance to 
the actions of several of these glycoproteins can be explained by modifications to 
common structures or mechanisms present in the receptors or alternatively 
variations of the intracellular growth regulatory pathways (Reddy et al, 1992). In a 
further step and to determine the mechanisms involved in the haematopoietic 
defect affecting the early precursors in non-acute aplastic anaemia, positively 
selected progenitors were studied with specific cytokine combinations in dose 
response studies to growth factors belonging to the two major receptor groups: the 
haemopoietin superfamily (G protein) and the tyrosine kinase group. 
6. 2 PATIENT POPULATION AND METHODOLOGY 
The patient population involved the sixteen individuals whose clinical data were 
reviewed in chapter two, while their bone marrow functions were defined on the 
CFU-bl assay in chapter five . Briefly, fifteen subjects that presented with acute 
aplasia and had responded to anti-lymphocyte globulin, or, upon relapse, 
cyclosporine immunosuppression, and additionally one individual who had 
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developed hypoplasia during the first trimester of pregnancy and elicited a partial 
response after a therapeutic abortion formed the study population. The median 
follow-up for this group has been four years (1-8). 
The controls involved seven haematologically normal individuals undergoing 
stemotomy for cardiac surgery under general anaesthesia. All gave consent to 
donate bone marrow for this study according to institutional guidelines of the 
University of Cape Town and Groote Schuur Hospital. 
6. 2. 1 Selection of the Haematopoietic Progenitor Cells 
Methodology for progenitor cell purification has been described in detail in 
chapters 3, 4 and 5. In short, a light density mononuclear population depleted of 
plastic adherent cells and lymphocytes (CAMPATH 1-M and complement) was 
incubated at 4° C with anti CD 34 murine antibody (MY 10, Beckman and 
Dickinson) for 30 minutes. Excess antibody was washed off and labelled cells were 
exposed to goat anti-mouse coated paramagnetic spheres (M-450, Dynal) at 4° C 
for 30 minutes. Selection was achieved after applying a magnet (MPC-1 , Dynal) to 
the side of the tube. This procedure was repeated once on the remaining unselected 
fraction. Beads were detached from selected cells after incubating the cell 
suspension at room temperature with a murine polyclonal IgG for 50 minutes 
(Detachabead, Dynal). Selected cells were re-suspended in culture medium at a cell 
concentration of 1-5 x 104/mL. Viability, morphological assessment and 
immunofluorescence studies were performed on the final suspension. 
6. 2. 2 Clonogenic Assays of the Selected Progenitor Cell Population of the 
Bone Marrow 
6. 2. 2. (a) Haematopoietic Growth Factors 
The following cytokines were employed: rh-IL 3 (specific activity of 107 U/mg), rh 
GM-CSF, G-CSF (specific activity 1 x 108 U/mg each), and c-kit ligand (SCF) 
(Amgen Thousand Oaks, California) at protein concentration of 0.5, 0.5 and 2 
mg/mL respectively. They were diluted to 103 hg/mL and kept at 4° C until use. 
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Erythropoietin was donated by Bioclones (Sandton, Transvaal) . Once reconstituted 
it was kept at 4° Cat a concentration of 1000 U/mL. 
6. 2. 2. (b) Clonogenic Assays. Dose Response 
Normal or aplastic positively selected CD 34 progenitors were cultured in vitro for 
fourteen days at 37° C in multi-cluster dishes (Nunclon Delta-Code 176740, UK) 
at a cell density of 1-5 x 103/mL in Iscove's modified Dulbecco's medium (IMDM, 
with L-Glutamine, Gibco). Cultures were supplemented with 30% FCS, 5 x 10-5 2-
mercaptoethanol, m 0.3% agar (final concentration) and incremental 
concentrations of Epo in the presence of IL3 10 hg/mL; of GM-CSF in 
combination with Epo 2 U/mL; increments of IL3 with Epo 2 U/mL and of c-kit 
ligand in association with Epo 2 U/mL and IL-3 10 hg/mL. 
Dose responses were constructed, based on the previously described study 
(chapter 3), where the starting growth factor concentration represented 25-50% of 
maximal clonal efficiency. The highest dose usually expressed concentrations well 
above plateau growth values for the cytokines tested. Additionally, G-CSF (10 
hg/mL) with or without c-kit ligand (20 hg/mL) were added to IL-3 10 hg/mL, and 
Epo 2U/mL, to determine the effect of GF addition. 
For permanent recording, cultures were fixed in 10% glutheraldehyde and stained 
in May-Grunewald-Giemsa. GM-CFUc were defined as myeloid aggregates 
(granulocytic, monocyte-macrophage or mixed) containing more than 40 cells. 
CFU-e were described as erythroid clusters of 4-100 cells, while BFUe were 
expressed as colonies containing more than 100 cells or when aggregates contained 
three or more sub-cultures. 
6. 2. 3 Statistical Analysis 
Due to the marked dispersion of the data, raw values of colony scores were 
subjected to logarithmic transformation with the formula Yl= In (Y + 1 ). Means, 
standard deviations and confidence intervals were calculated using the normalised 
data. A two-way analysis of variance was employed to determine the significance 
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of differences between groups of cultures or a single culture versus a control 
group. Mulivariate analysis was performed to define the correlation between sets 
of observations, discriminant functions and clustering of data (Morrison, 1976). 
6. 3 RESULTS OF DOSE RESPONSE AND GROWTH FACTOR 
COMBINATION STUDIES 
6. 3. 1 Selection of the Bone Marrow Progenitor Cells 
Results of the selection for the CD 34+ population have been presented in Chapter 
5. Briefly, aplastic mononuclear cells had significantly lower cell numbers that 
emitted fluorescence after being labelled with anti-CD 34 antibody (0.65%, SD 
0.35 vs 1.60% SD, 1.38; p<0.05). The median corrected number of selected 
progenitors was also lower at 0.116 x 106 (normal donors : 0.539 x 106; p= 0.18) 
with cell viability in excess of 90% (Table 5. 2, page 82). 
6. 3. 1. (a) Clonogenic Assays. Dose Response (Table 6. 1) 
6. 3. 1. (a). i Erythropoietin (Epo) [Fig. N° 6. 1. (a)] 
Incremental concentrations of Epo O. 2, 2, 10 and 100 U in the presence of IL3 10 
hg/mL showed that in both the patients and controls, the number of BFU-e 
increased with hormone concentrations. However, in the aplastic group these were 
significantly lower at 0.2, 2 and 10 U/mL (p < 0.001 , 0.001 and 0.05). In contrast 
with the normal group, erythroid growth in the aplastic progenitors continued 
improving significantly in a linear fashion from the lowest concentration to 100 
U/mL (p < 0.01), without achieving plateau growth and approaching control 
values. The number of CFU-e were lower at all concentrations, but did not achieve 
significance (p > 0.05). CFU-gm were unaffected by changes in Epo concentration. 
At plateau concentrations, normal and aplastic progenitors showed adequate 
haemoglobinization, with formation of massive macroscopic multi-lobed colonies, 
and stimulation of immature bursts (more than 7 subclones of mainly blastic cells 
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with poor haemoglobinization). Mixed colonies were also present in both aplastic 
and control cultures at 10 and 100 U. 
6. 3. 1. (a). ii Granulocyte-Macrophage Colony Stimulating Factor 
(GM-CSF) [Fig. N° 6. 1. (a)] 
Control and aplastic progenitors were cultured with Epo 2 U/mL and GM-CSF at 
concentrations of 0.1, 1, 10 and 50 hg/mL. Among normal cultures, a linear 
response was found for CFU-gm commencing at 0.1 hg/mL, while stimulation for 
BFU-e and CFU-e appeared already at a plateau. 
Aplastic progenitors again displayed an elevation in the numbers of all colony 
types, commencing with significantly lower scores than those of normal cultures 
for BFU-e at 0.1 and 1 hg/mL (p < 0.001 and 0.001) and CFU-gm at 0.1 and 1 
hg/mL (p < 0.025 and 0.01), but colony numbers continued increasing at 10 and 50 
hg/mL up to control values. In the patients, from the starting concentration, the 
increment in the number of BFU-e and CFU-gm were significant at 10 (p < 0.05 
and 0.01) and 50 hg/mL (p < 0.01) respectively. At top cytokine concentration, 
CFU-mix as well as macroscopic BFU-e and CFU-gm colonies were also present 
in the patient population. 
6. 3. 1. (a). iii Interleukin 3 (IL3) [Fig N° 6. 1. (b)] 
In the presence of Epo 2 U/mL, IL 3 gave lineal increments m the normal 
precursors, with maximal clonal expansion at 10 hg/mL for all colony types. At 50 
hg/mL a plateau effect on CFU-gm and some inhibitory action on the erythroid 
colonies was noted. 
In the study group, proportional increments in the three colony types were again 
observed and it was significant for BFU-e at the highest concentration (p < 0.05). 
Compared to control cultures, colony numbers from aplastic clones were 
significantly lower for BFU-e and CFU-e at 1 hg/mL (p < 0.001 and 0.025) and 
BFU-e at 10 hg/mL (p < 0.001). However, at 50 hg/mL, BFU-e and CFU-gm 
showed a combined increment in colony numbers of 109%, achieving similar 
TABLE 6.1 
CLONOGENIC ASSAYS 
TYPE OF COLONY 
CYTOKINE BFU-e CFU-e CFU-gm 
COMBINATION APLASTIC CONTROL APLASTIC CONTROL APLASTIC CONTROL 
MEAN SD MEAN SD MEAN SD MEAN so MEAN SD MEAN SD 
I I I I I T 
IL 3 10 hg + Erythropoietin n=ll n=7 n=ll n=7 n=ll n=7 
Eoo: I I I I I I 
0.2 U/mL 0.61 0.95 2.90 0.69 2.96 0.78 3.93 0.52 2.67 1.26 3.02 1.66 
n=15 n=7 n=15 n=7 n=l5 n=7 
2U/mL 2.10 1.32 3.97 0.54 3.50 1.08 4.18 0.55 2.94 0.93 3.74 0.62 
10 U/mL 3.03 1.18 4.14 0.49 2.99 1.25 3.83 0.87 2.95 1.07 3.42 1.14 
100 U/mL 3.57 0.71 3.96 0.54 3.34 0.97 3.97 0.91 3.25 0.68 3.72 0.86 
Epo 2 U/mL + GM-CSF n=7 n=7 n=7 n=7 n=7 n=7 
GM-CSF: I I I I I I 
0.1 hg/mL 1.62 0.95 3.66 0.71 3.23 1.37 3.53 1.19 1.12 1.26 2.28 1.24 
n=15 n=7 n=15 n=7 n=15 n=7 
lh!!lmL 1.67 1.27 3.37 0.40 2.87 1.27 3.65 1.19 1.51 1.72 3.10 0.77 
-
10 hg/mL 2.59 0.99 3.04 1.09 2.94 1.23 3.70 1.16 3.02 1.13 2.91 1.52 
50 h!!/mL 2.98 0.70 3.57 0.82 3.23 1.12 3.68 1.03 3.88 0.71 3.63 0.44 
Epo 2 U/mL + Interleukin 3 n=15 n=7 n=15 n=7 n=15 n=7 
IL-3: 
1 h!!/mL 1.50 1.06 3.29 0.76 2.76 1.05 3.85 1.19 1.62 1.26 2.42 1.13 
10 hg/mL 2.10 1.32 3.97 0.54 3.50 1.08 4.18 0.55 2.94 0.93 3.74 0.62 
50 h!!/mL 2.94 0.98 3.02 0.96 3.19 1.03 3.73 1.13 3.43 0.68 3.37 1.61 
Epo 2 U/mL+IL-3 10 hg/mL 
n=7 n=S n=7 n=S n=7 n=S + Stem Cell Factor 
SCF: 
lhg/mL 1.76 1.69 4.13 0.42 2.61 0.92 3.71 1.55 3.11 1.08 4.21 0.53 
20 h!!/mL 3.65 1.01 4.57 0.54 2.84 1.26 3.26 1.37 3.81 0.61 4.75 0.47 
200 h!!/mL 3.99 0.50 4.26 0.71 2.68 1.43 3.36 1.17 4.29 1.24 4.72 0.89 
Dose response to growth factors combinations. Bold figures in squares denote significance: p 
< 0.05. Results are ex'Pressed as mean (Mean) and standard deviations (SD) ofY1= (log Y+l). 
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values to those of control progenitors (Fig N° 6. 2, page 101). At the maximal 
cytokines levels, mixed clones and colonies of immature blasts were also present in 
the cultures of some of the patients. 
6. 3. 1. (a). iv Stem Cell Factor (c-kit ligand) [Fig N° 6. 1. (b)] 
Normal and aplastic progenitors were cultured with stem cell factor at 
concentrations of 1, 20 and 200 hg/mL in combination with Epo 2 U and IL3 10 
hg/mL. In the normal assays, results showed that the addition of c-kit ligand to the 
basic IL3+Epo combination led to a marked enhancement in BFU-e and CFU-gm 
by 82.94% and 154.87% respectively (Fig NO 6. 2, page 101). This increment 
achieved significance for the granulocytic colonies at 200 hg/mL (p < 0.05). 
In subjects with aplasia, increments in this cytokine up to 200 hg/mL also resulted 
in a significant enhancement in the BFU-e and CFU-gm to 263 .3 and 300 % 
respectively (p < 0.01 and 0.05) over the basal IL-3 10 hg/mL + Epo 2 U/mL 
combination. Therefore, values of cultures were significantly lower only for BFU-e 
at 1 hg/mL (p < 0.05) . Although at this concentration the stimulating effects were 
provided mainly by the basic IL-3 + Epo combination (Lowrey et al, 1992). At 
effective concentrations (320 hg/mL ), results were not significantly different from 
those of control cultures. Similar to their normal counterparts, at the highest 
cytokine concentration, marked increments in colony sizes with macroscopic 
mixed, myeloid and erythroid clones were also observed. 
In summary, results of dose responses in the mixed colony assay showed a 
significant reduction in the sensitivity of CD 34+ cells of patients with aplastic 
anaemia to Epo, 11-3 and GM-CSF. Of interest, at pharmacological concentrations 
the clonogenic potential improved and even matched that of controls. 
In contrast, exposure of aplastic progenitors to concentrations of c-kit ligand 
which were effective in normals (> 20 hg/mL ), led to significant clonogenic 
enhancement, which was superior to top concentrations of any other growth factor 
96 
combination, resulting in increments which were proportionally higher than those 
of normal cultures (Fig NO 6. 2, page 101). These growth improvements in the 
aplastic cultures led to colony numbers which were not significantly different from 
those of normal precursors. 
6. 3. 1. (b) Growth Factors in Combinations (Table 6. 2) 
The addition of fixed concentrations of G-CSF 10 hg/mL to IL 3 and Epo, or this 
combination with SCF at 20 hg/mL, showed conflicting results but confirmed that 
under appropriate stimulation, aplastic progenitors are able to respond adequately 
(Table 6. 2, page 97 and Fig. 6. 2, page 101). 
G-CSF added to the patients' cultures had a marginal effect on erythroid growth. 
This growth remained significantly lower than that of control studies (p < 0.001), 
but led to an enhancement of the myeloid colonies over the basal IL-3 and Epo 
combination by 101.43% (p < 0.02), and to results not different from those of 
control. The four cytokine combination also gave significant improvement in the 
clonogenic potential up to 147 and 231 % for BFU-e and CFU-gm respectively, 
which was proportionately higher than the growth registered in control cultures. 
With this combination in the aplastic studies, massive erythroid bursts of both 
mature and immature BFU-e and macroscopic granulocytic colonies were obvious. 
6. 3. 2 Multivariant Analysis 
Studies performed on the logarithmic transformation of the aplastic mixed colony 
assays determined that the combination of Epo 2 U/mL with IL-3 10 hg/mL could 
discriminate 100% of the patients from the control population for both BFU-e and 
CFU-gm colonies (discriminant analysis). Multivariant analysis also segregated the 
results for all three colony types in cultures supplemented with c-kit ligand at 
biologically effective concentrations from the remaining dose response studies. 
Interpretation of these data would suggest that cultures containing SCF were 
affected by independent interactions from those induced by the other growth factor 
combinations. 
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6. 4 DISCUSSION OF THE RESULTS 
The data presented in Chapter five confirmed that the bone marrow stroma in 
aplasia supported haematopoiesis adequately, suggesting that in this disease the 
primary defect lay within the haematopoietic stem cell . 
TABLE6.2 
GROWTH FACTORS IN COMBINATIONS 
TYPE OF COLONY 
CYTOKINE BFU-e CFU-e CFU-gm 
COMBINATION 
APLASTIC CONTROL APLASTIC CONTROL APLASTIC CONTROL 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
I I I I I I 
n=ll n=7 n=ll n=7 n=ll n=7 
EPO 0.2 U/mL IL-310 hg/mL ~0.95 2.901 0.69 ~ 0.78 3.931 0.52 2.6711.26 3.0211.66 
n=15 n=7 n=15 n=7 n=15 n=7 
EPO 2 U/mL IL-3 10 hg/mL ~ 1.32 3.971 0.54 3.501 1.08 4.181 0.55 2.941 0.93 3.741 0.62 
n=15 n=7 n=15 n=7 n=15 n=7 -EPO 2 U/mL IL-3 10 hg/mL 2.47 1.35 4.28 0.68 3.03 1.25 3.71 1.20 3.73 0.86 4.24 0.72 -G-CSF 10 hg/mL 
n=7 n=5 n=7 n=5 n=7 n=5 
EPO 2 U/mL IL-3 10 hg/mL 3.65 1.01 4.57 0.54 2.84 1.26 3.26 1.3? 3.81 0.6 1 4.75 0.4? 
SCF20hg/mL 
n=7 n=5 n=7 n=5 n=7 n=5 
-EPO 2 U/mL IL-3 10 hg/mL 3.00 1.41 4.66 0.66 2.39 1.35 2.80 I. SC 4.24 0.94 5.00 0.48 
SCF 20 hg/mL G-CSF 10 hg/mL -
Results of in vitro culture of aplastic and control CD 34 + progenitors to the basic IL-3 10 
hg/mL with Epo 0.2 U/mL or Epo 2 U/mL and the addition of G-CSF, SCF or both. 
Values in bold denote significance p < 0.05 . Results are ex-pressed as mean (Mean) and 
standard deviations (SD) of Y1= (log Y+ 1). 
To further investigate the possible mechanisms of this lesion, and to determine if 
the hypoproliferative state could be reversed by more intense GF stimulation, 
selected CD 34+ progenitors greatly depleted of accessory cells were studied in 
dose responses to recombinant growth factors in various combinations. These 
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studies were designed to test the proliferative mechanisms activated by the two 
super-families of haematopoietic receptors: the G protein superfamily and those 
belonging to the tyrosine kinase type. Culture results showed that aplastic 
progenitors have a significantly lower sensitivity to Epo, IL-3 , GM-CSF than do 
controls. Furthermore, it has been possible to document for the first time that in 
aplasia, the clonal potential of the haematopoietic progenitors is preserved since, at 
the highest cytokine concentrations, colony numbers matched control values. 
This point is also stressed by those studies showing that addition of G-CSF again 
potentiated the actions of IL-3 at 10 hg/mL on myeloid progenitors and led to an 
efficient stimulation of the aplastic granulocytic colonies to levels not significantly 
different from those of normal precursors while BFU-e results remained 
unaffected. 
These findings, however, appear at vanance with other publications, where 
mononuclear cells from patients with acute aplasia, or those responding to 
immunosuppressive therapy were cultured in the presence of incremental 
concentrations of Epo (Aoki et al, 1988) or GM-CSF (Bacigalupo et al, 1991). 
Here results demonstrated generally poor in vitro proliferative responses to single 
cytokines. Furthermore, in a limited number of transfusion independent patients, at 
pharmacological concentrations of growth factors, improvements in the clonogenic 
growth were observed, although median values failed to match control results. 
Nevertheless, as in these reports, no positive selection for the clonogenic 
precursors was attempted, progenitors were cultured in unknown numbers and 
contaminated with accessory cells. In this disease, adherent and non-adhesive 
accessory cell, present in the bone marrow inoculum, have been described as 
inhibiting normal bone marrow growth (Bacigalupo 1984, Merchav, 1988). These 
technical distinctions may explain the differences in the results. Alternatively, INF-
g and TNF are produced excessively by aplastic accessory cells (Hintenberger, 
1988). At high GM-CSF concentrations, this contaminating population may further 
induce the release of TNF (Cannistra & Griffin 1988), or other regulators, limiting 
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Fig. N° 6. 1 (a): Dose response of aplastic and control CD 34+ cells exposed to Epo 0.2, 2, and 
10 U/mL (with IL-3 10 hg/mL) and Gm-CSF 0.1, 1, 10 and 50 hg/mL in the presence of Epo 2 
U/mL. With GM-SCF differences at 0.1 and 10 hg/mL were significant for BFU-e and CFU-gm 
colonies, while for CFU-e only at the lowest concentration.* denotes significance of p < 0.05 . 
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Fig. N° 6. 1 (b): Comparative results of clonogenic growth from patients with aplastic anaemia to 
normal individuals. Dose response to Il-3 1, 10 and 50 hg/mL (with Epo 2 U/mL) and SCF at 1, 
20 and 200 hg/mL supplemented with IL-3 IO hg/mL and Epo 2 U/mL. * denotes significance of 
p < 0.05 . 
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These experiments have also documented adequate responsiveness of aplastic 
precursors to c-kit ligand when cultured in the presence of Epo and IL-3 . Despite a 
sub-optimal response to the more restricted stirnulators (Epo 2 U/mL and IL-3 10 
hg/mL ), at effective concentrations stem cell factor significantly corrected this 






























Fig. N° 6. 2: Per cent change in clonogenic growth over the basal IL-3 10 hg/mL, Epo 2 U/mL 
expressed as 1, by growth factor combinations. Values represent % difference for each colony 
type (see also Table ·6. 2). Each pair of bars represents respectively values for "Aplastic" and 
"Control" experiments. 
C-kit ligand has little clonogenic activity on its own (Lowrey et al, 1992). 
However, as seen in this study, at appropriate concentrations it is synergistic with 
the actions of other early acting cytokines. In aplastic progenitors the proportional 
increment in the colony numbers was superior to that of control studies. It 
exceeded the basic IL-3 10 hg/mL + Epo 2 U/mL by 500% for erythroid and 
myeloid colonies together, leading to the highest scores for BFU-e and CFU-gm 
(Fig N° 6. 2). It resulted in clonogenic yields not significantly different from 
control cultures, suggesting again that the clonal potential in this disease remains 
preserved. 
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Similarly to normal progenitors, remarkable enhancements in colony size and 
haemoglobinization of BFU-e was observed, with macroscopic CFU-gm and 
mixed colonies. Multivariate analysis indicated a segregation of cultures 
supplemented with effective concentrations of c-kit ligand, from those grown with 
other GF combinations, suggesting independent interactions affecting the cultures 
containing this growth factor. These data appear to be in good agreement with 
another study in a similar patient population, employing unfractionated marrow 
mononuclear cells and confirmed by 3H Thymidine uptake studies (Wodnar-
Filipowitz et al, 1992). 
Since the results of the CFU-bl assay show that cells in the aplastic stroma do not 
exert excessive inhibition on control CD 34+ progenitors (Chapter 5), while 
appropriate response to certain growth factors is observed only at high GF 
concentration or in the presence of stem cell factor, alterations in the signalling 
pathways for cell division are consequently favoured . 
Reduction in the response to GF may result from abnormalities in the receptor 
densities or affinities for the ligands leading to sub-optimal clonogenic growth. 
Additionally, soluble forms or binding proteins of these receptors exist, secreted 
naturally into the microenvironment or alternatively originating as proteolytic 
cleavage products of transmembrane molecules. Such binding proteins can 
potentially function as inhibitors to the action of their ligands in a feedback 
regulation (Olsson et al, 1992). 
However in this study, the described derangements in the responses to GF ranged 
widely over three cytokines, suggesting alterations in shared structures or pathway 
signalling for cell division. Receptors for IL-3 , IL-4, IL-7 Gm-CSF G-CSF and 
Epo (but not M-CSF or c-kit which have tyrosine kinase activity) belong to a 
common receptor family with some structural similarities (Demetri et al, 1991 , 
Gasson et al, 1991 , Pouyssegur et al, 1992). They form part of the growing 
transmembrane GTP-binding group of proteins which control a series of second 
messenger molecules including adenylate cyclase, cGMP phosphodiesterase, 
phospholipases and ion channels (Gillman et al, 1989). Since cooperation and 
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integration of signals between pathways are important in the mitogenic response 
(Pouyssegur, 1992), phosphorylation of c-kit receptor by its ligand may lead to 
correction of the signals relayed by the abnormal G family of proteins and result in 
rectification of the mitogenic response. This may have important therapeutic 
implications. 
It is concluded that in patients with aplastic ·anaemia treated with ALG+HDMP, 
intrinsic abnormalities in the CD 34+ population result in subnormal clonogenic 
growth. Alterations in the cytokine receptors' structures or affinities or damage to 
common intracellular signalling mechanisms for cell division are proposed. 
Whether during the initial presentation, a more profound abnormality of the same 
pathways leads to the severe pancytopenia, or this derangement is a characteristic 
of the escape population that survives the original attack, remains to be 
determined. 
CHAPTER 7 
SUMMARY OF THE OBSERVATIONS AND FINAL 
CONCLUSIONS 
7. 1 INTRODUCTION 
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Aplastic anaemia has attracted considerable attention since its initial description 
more than 100 years ago by Ehrlich (1888) . The points of greatest interest were 
the heterogeneous clinical presentation, multiplicity of etiologic associations, its 
relation to acute leukaemia (Tichelli et al, 1988 [ a and b], Orlandi et al, 1988) 
and in those with more intense manifestations, irreversible outcome from 
catastrophic bleeding or overwhelming infections (Camitta & Thomas, 1978). 
Based on models that showed that infusions of allogeneic marrow could rescue 
animals from the irreversible pancytopenia that followed supralethal doses of 
irradiation or cytotoxics (Till & McCalluch, 1964), clinical trials in patients 
with aplasia have confirmed the effectiveness of bone marrow transplantation in 
those with an HLA compatible sibling, particularly in patients with the very 
severe variety (Gordon-Smith, 1987). 
However , experience demonstrated that the infusion of sibling bone marrow 
without preconditioning with cytotoxics resulted in graft losses in a third of 
syngeneic transplants (Appelbaum et al, 1980) even in those that had received 
intense preparation. Allograft failure was occasionally followed by autologous 
recovery of the haematopoiesis. This led to the conclusion that at least in some 
patients this disorder could be associated with abnormalities in the bone marrow 
microenvironment or of the immune system. 
Further points favouring the immunological basis of this disease, were provided 
by the frequent finding of bone marrow inflammatory infiltrates in biopsies 
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during the initial presentation (Haak, 1978, de Planque et al, 1989). Moreover, 
in vitro studies showed that when accessory cells from the marrow of patients 
with aplasia were cocultured with aplastic or normal myeloid progenitors they 
appeared to inhibit clonogenic growth (Torok-Storb 1980, Merchav et al, 1988). 
This suppression was reversed by the removal of adherent cells and T 
lymphocytes from the cultures (Singer, 1989). Furthermore, overproduction of 
certain products derived from the immune system such as interferon gamma 
(Zoumbos et al, 1985), and neopterin (Hinterberger et al, 1988) appeared to 
reverse after ALG therapy. 
In the clinical context, encouraging results were reported with anti-lymphocyte 
globulin as preconditioning for haploidentical bone marrow support (Mathe, 
1970, Mathe & Schwarzberg, 1976, Camitta & Thomas, 1984) or without graft 
infusions (Champlin et al, 1983). However , it then became more obvious that in 
aplasia an immunological activation triggered by idiosyncratic reaction to drugs, 
chemicals, viral infections and even pregnancy (Van Besien, 1991 , Aitchison 
1989) resulted in intense marrow damage. Confirmation of this theory was 
initially provided by anecdotal reports, followed by retrospective studies (Speck 
et al, 1986, Novitzky et al, 1991) and validated by controlled clinical trials 
(Champlin et al, 1983). 
It is noticeable that, following this therapy haemopoietic recovery is slow and 
often incomplete, while in 20% of the patients this disease may recur. 
Furthermore, in some responding to this treatment, morphological and 
functional abnormalities of the mature blood elements have been described (de 
Planque et al, 1989, [a and b], Chapter 2 this thesis) , while extended follow-up 
has suggested that in 15-58 % of patients, clonal diseases such as PNH, MDS or 
acute leukaemia may develop (Tichelli et al, 1988 [a and b]). 
Some recent studies that investigated the pathogenesis of this disorder concluded 
that in both acute and non-acute aplasia the bone marrow stroma was abnormal, 
with altered monocyte maturation and deranged fibroblasts and monocytic 
functions (Hotta et al, 1986, Juneja et al, 1984, Anderseen et al, 1989). This 
notion was further strengthened by certain similarities between this disease and 
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the murine model carrying the Steel mutation (Si/Sid), which is characterised by 
a macrocytic anaemia associated with defective stromal cell environment. Here 
the disorder could not be cured by infusing normal marrow stem cells, but 
improved by implantation of normal splenic stromal tissue (Becker & 
McCulloch, 1965, Wolf 1978). 
This evidence suggested that at least in some systems the pancytopenia could be 
due to abnormal cell interactions within the microenvironment. Alternatively, it 
could be argued that the unrestrained action of cells of the immune system 
residing in the bone marrow could lead to overactive secretion of negative 
regulators and to marrow failure. 
Due to low numbers of clonable progenitors, there are limited data on the 
growth potential during the acute stage of the disease. Nevertheless, in non-
acute aplasia, even despite marked improvement in the blood counts, myeloid 
precursors appear to express sub-optimal clonogenic growth when cultured in 
the presence of recombinant growth factors (Marsh et al, 1991 , Novitzky et al, 
1991). Moreover, in vivo these patients may respond to pharmacological doses 
of colony stimulating factors , with significant expansion of the lineage under 
stimulation. However, these responses are unsustained after discontinuation of 
the cytokines (Vadham-Raj et al, 1989, Bessho et al, 1990, et al, Kojima et al , 
1991). 
7. 2 MAIN OBSERVATIONS OF THE THESIS 
In the present study , a cohort of patients with aplastic anaemia treated with a 
uniform protocol of immunosuppression with anti-lymphocyte globulin and 
high-dose methyl-prednisolone has been followed up for a median of four years. 
In this homogeneously treated group it was initially noted that, despite 
haematological recovery , some patients continued to display various 
morphological and functional abnormalities. Data presented in chapter 2 
confirmed widespread dysplasia in one or more myeloid cell lines. Although the 
number of blasts always remained normal , the biopsy material showed ALIP 
formation and , in some patients, significant reticulin fibrosis. 
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Functional studies of the blood elements showed that the bleeding time was 
prolonged in ten of fifteen patients, and significant abnormalities were detected 
in the platelet aggregation, generation of oxygen radicals by neutrophils and 
phagocytosis. These results are consistent with similar observations reported in 
patients with congenital anaemias where, despite the normal number of receptors 
and affinity for the ligand (Kyas et al, 1992; Rauprich et al, 1991), intracellular 
abnormalities in the response to G-CSF were detected in mature blood 
leukocytes (Kurtzberg et al, 1992, Roesler et al, 1992). 
Furthermore, cytogenetic studies in 30% of patients revealed chromatid or 
chromosomal aberrations and breakage in a significant proportion of the bone 
marrow cells. All these features have characteristically been described in 
myelodysplastic syndromes. Nevertheless, as blood counts continued to improve 
significantly over the median follow-up period of four years, the diagnosis of 
MDS could not be sustained . 
Following the initial pilot study (Chapter 4) , that showed that clonable CD 34+ 
cells in the marrow of patients with acute aplasia were markedly reduced, it was 
felt that with the methodology at hand extensive investigations of this cell 
population would be unsuccessful. Nevertheless , these limited studies suggested 
that in untreated patients, their confluent bone marrow stroma supported the 
proliferation of normal CFU-bl adequately . On the basis of this initial 
assessment, further work was then directed at studying the clonogenic defect in 
the bone marrow that restores haematopoiesis following ALG therapy , 
employing enriched progenitors devoid of accessory cells. 
To analyse the nature of these abnormalities and to define the relevant merits of 
each of the previously proposed mechanisms, a system was developed whereby 
aplastic and normal stroma were cultured in vitro, while clonogenic cells that 
had been enriched for the CD 34 membrane surface antigen could be tested in 
cross culture studies on these preformed bone marrow adherent layers (Chapters 
3, 4 and 5). 
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7. 3 SIGNIFICANT CONCLUSIONS OF THIS THESIS 
Comparative studies of the marrow stroma from sixteen subjects in partial or 
complete response following standard immunosuppression with control adherent 
layers , failed to demonstrate obvious morphological differences. On the 
cytochemical stains, the cell proportions between the two groups were similar, 
and when seeded with normal CD 34 positive cells they supported the growth of 
blastic colonies. This resulted in plating efficiencies that matched those of 
control stroma. 
The obvious difference resided in the aplastic CD 34+ population. When 
incubated on normal stroma, these progenitors led to significantly lower CPU-bl 
compared to values obtained from control precursors incubated on normal or 
aplastic layers. These data would suggest that levels of negative regulators in 
aplastic stroma are not significantly higher than those of control layers since 
normal CPU-bl formation was well supported. 
Moreover , this study was able to document for the first time that in this disease 
the fraction of dividing cells within the adherent and non-adherent CD 34 + 
populations was proportionately reduced and the clonogenic deficit appeared 
unrelated to abnormalities in the adhesiveness of the precursors on to stroma. 
Clonogenic cells in the bone marrow possess receptors to growth factors 
belonging to two super families: the G protein type that includes Epo , IL-2, IL-
3 , IL-4, IL-5 , IL-6 , IL-7 , GM-CSP and G-CSP, typically composed of multiple 
subunits necessary for high-affinity binding and cell signalling (Olsson 1992) 
and those belonging to the tyrosine kinase group, represented by platelet derived 
growth factor (PDGP), Macrophage-CSP (CSP-1) and c-kit (SCP). 
In trying to clarify further the mechanisms of the described sub-optimal 
clonogenic responses in aplasia, it was decided to focus on the progenitor cells 
and determine their proliferative capacity by constructing dose response studies 
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to growth factors in specific combinations. To test the integrity of the mitotic 
signals, Epo, IL-3 and GM-CSF, ligands belonging to the G type of receptor 
were selected . For the second receptor group, c-kit ligand was chosen. This was 
done because M-CSF can induce both positive and negative regulatory signals 
and results may therefore, be difficult to interpret (Wang et al, 1992). It was 
also preferred for two additional reasons. Firstly because this growth factor 
interacts with an earlier precursor population affecting the development of all 
cell lines , and, lastly, because murine models of genetic anaemia (S/Sl and 
W/W) are associated with abnormalities in the expression of the SCF and its 
receptor. 
Although SCF has little activity on its own (Lowrey , 1992), it has additive 
effects in combination with other GF. Since data of the basic IL-3 + Epo 
admixture were available , any additional effect would become obvious. Results 
of these dose response studies in patients with non-acute aplasia confirmed that 
at low cytokine concentrations sub-optimal clonogenic responses were observed. 
However, these were followed by significant improvements in the colony 
numbers at high GF levels. 
In this study , it is documented for the first time that when purified populations 
of CD 34+ cells are used, at the highest concentrations of Epo, IL-3 , and GM-
CSF the clonogenic output is not significantly different from normal. 
Furthermore, in combinations containing effective concentrations of c-kit 
ligand, a significant enhancement in the clonal efficiency of 263.3 and 299,8% 
for BFU-e and CFU-gm over the basic Epo-IL-3 was obtained, respectively . 
This improvement was proportionately higher than that of control cultures 
(Table 6. 2, page 97 and Fig. N° 6. 2, page 101) leading to colony numbers not 
significantly different from those derived from normal progenitors. Moreover , 
multivariate analysis demonstrated clustering of the results of cultures containing 
effective concentrations of c-kit ligand . These results suggest interactions 
(mechanisms?) that differ from those supplemented with the other growth factor 
combinations. 
110 
These data also demonstrate for the first time that the mitotic potential of the 
aplastic stem cells may not be significantly different from normal, but that the 
sensitivity of these progenitors to peptides interacting with the G super-family of 
receptors is deranged, explaining the observed clinical abnormalities. 
Similarly , clonogenic responses to SCF in bone marrow cells from patients with 
congenital aplastic syndromes such as Diamond Blackfan or Fanconi' s anaemia 
appeared enhanced compared to the stimulatory signals provided by IL-3 
(Abkowitz et al, 1992, Alter et al, 1992). Although in vitro laboratory data may 
not be predictable for clinical responses to cytokines, these data suggest that 
therapeutic trials of stem cell factor in patients with these disorders should be 
strongly considered. 
7. 4 FINAL COMMENTS. 
The studies described in this thesis do not provide further data concerning the 
specific mechanism that lead haematopoietic progenitors to respond sub-
optimally to GF. However, explanations for these observations could include 
altered interactions between specific cytokine receptors and their ligands, either 
through changes in the affinity or membrane surface density. Additionally , 
soluble forms (binding proteins) of these receptors exist for both families, 
originating, probably, from proteolytic cleavage products of transmembrane 
molecules or alternatively, they are produced by natural secretion. Such binding 
proteins can help in the protection and transport of these cytokines or to the 
contrary , they can potentially function as inhibitors to the action of the ligand in 
feedback regulation (Olsson et al, 1992). 
Furthermore , alterations at the level of the receptor structure or oligomerization, 
can also lead to loss of affinity with the ligand, or increases in the production of 
the soluble receptor fractions resulting in sub-optimal cell stimulation that can 
be overcome with higher GFs concentrations. 
However, as the inappropriate clonogenic responses were elicited to a wide 
range of GFs, future investigations directed at these activation cascades may 
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reveal abnormalities in the signalling for cell division . Indeed, malignant 
myeloproliferation with overactive responses to haematopoietic peptides (Dai et 
al, 1992) and aplastic anaemia could represent opposites of a spectrum 
originating from abnormalities in the activation sequences that lead to the G1-M 
progression in the cell cycle and replication of the progenitor cells. 
It would be attractive to suggest that abnormal responses to these growth factors 
have common intracellular defects resulting in the subnormal responses to these 
cytokines. The Haemopoietin super-family are part of the growing 
transmembrane GTP-binding proteins that control a series of second messenger 
molecules (Gilman et al, 1989). The activation of these proteins is associated 
with Ca++ release from intracellular stores (Spivak et al, 1992, Reddy et al, 
1992), formation of diacylglycerol and inositol triphosphate , activation of 
calmodulin and progression into cell cycle. 
Moreover , specific calmodulin binding proteins have been described associated 
to the intranuclear enzyme DNA polymerase a and a 68 Kd binding protein that 
controls the terminal events required for the onset of DNA replication. The 
nuclear localization of this binding protein leads to transition from G1 to S phase 
in the cell cycle and has been found to be common to GM-CSF , G-CSF , IL-3 or 
IL-6 but not for CSF-1 (Reddy et al, 1992). Alterations in this calmodulin 
binding molecule , could represent a possible target site in the chronic 
hypoproliferation of aplasia. 
Progression to S phase requires cooperation of multiple intracellular pathways, 
and less potent GF may need the combined action of several signals to induce a 
strong mitogenic response . This was clearly shown by the additive effect 
provided by G-CSF in the aplastic cultures (Fig N° 6. 2, page 101). 
Pleiotropic programs are common to all growth factors as most responses (ion 
changes, Na+-H+ antiporter, Na+ , K+ ci- co-transport activation) and early 
gene transcriptions are initiated and maintained by phosphorylation changes 
occurring at serine or threonine residues. Switch kinases activated by tyrosine 
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kinase, protein kinase-C and G-coupled receptors, appear to integrate at early 
points complex networks of kinase-kinase cascades leading to activation of 
multiple cell targets. 
One such early convergence is represented by MAP-kinases that need 
phosphorylation of both tyrosine and threonine residues for full activation 
(Pouyssegur et al, 1992). Derangements of any of these mechanisms, would 
disadvantage the cell under study in the finely tuned balance between positive 
and negative regulators that normally control haematopoiesis. Since cooperation 
and integration of signals between pathways are important in the mitogenic 
response (Poyssegur , 1992), phosphorylation of the c-kit receptor by its ligand, 
may correct the signals relayed by the abnormal G family of proteins and result 
in the improvement of the mitogenic response . 
In summary , these studies have confirmed that in aplastic anaemia the stroma 
does not exert excessive suppressive actions on the clonogenic cells tested 
(CFU-bl) . They suggest conversely , that the defect lies within this progenitor 
population demonstrating for the first time that the dividing fractions of both 
adherent and non-adhesive precursors are affected. 
It has also provided original data showing that despite a sub optimal clonal 
efficiency at physiological concentrations of growth factors , the clonogenic 
potential of the aplastic progenitors that repopulate the bone marrow remains 
preserved. It has also been able to provide new compelling data that this poor 
responsiveness was restricted to the ligands belonging to the G super family of 
receptors and demonstrates that the mechanisms involved in the murine genetic 
anaemia (SI/Sid and W/WV) do not operate in the acquired presentation of the 
human disease. 
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